WO2016062285A1 - 神经***疾病用药在制备抗癌医药组合物中的应用 - Google Patents

神经***疾病用药在制备抗癌医药组合物中的应用 Download PDF

Info

Publication number
WO2016062285A1
WO2016062285A1 PCT/CN2015/092775 CN2015092775W WO2016062285A1 WO 2016062285 A1 WO2016062285 A1 WO 2016062285A1 CN 2015092775 W CN2015092775 W CN 2015092775W WO 2016062285 A1 WO2016062285 A1 WO 2016062285A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
hcl
hydrochloride
inhibitory effect
skin
Prior art date
Application number
PCT/CN2015/092775
Other languages
English (en)
French (fr)
Inventor
陈丘泓
庄秀美
萧乃文
梁瑞岳
陈筱彤
Original Assignee
朗齐生物医学股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朗齐生物医学股份有限公司 filed Critical 朗齐生物医学股份有限公司
Publication of WO2016062285A1 publication Critical patent/WO2016062285A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to the application of new indications for various neurological diseases, in particular, the plurality of drugs are used in clinical experiments and have the purpose of inhibiting various cancers.
  • Cancer has long been the leading cause of death worldwide, and the number of cancer patients has increased year by year. Therefore, treating cancer has become an important issue.
  • the treatment of cancer can be divided into surgical treatment, radiation therapy, chemotherapy and target treatment.
  • cancer drug treatment is intended to prevent cancer cells from replicating and dividing to block the spread and spread of tumors.
  • chemotherapy chemotherapy or target treatment
  • cancer drug treatment is intended to prevent cancer cells from replicating and dividing to block the spread and spread of tumors.
  • chemotherapeutic drugs and target treatment hoping to kill cancer cells by different mechanisms to improve the therapeutic effect, but in fact, patients often react to the treatment of drugs Not good.
  • many cancer cells successively develop drug resistance, which greatly reduces the effectiveness of drug use, and ultimately leads to failure of cancer treatment.
  • the present invention aims at the development of new indications for various drugs through clinical trials, and achieves the goal of new use of old drugs.
  • the experimental design results show that the neurological disease has no or only minimal toxicity to normal cells, but as to whether the neurological disease has a selective effect between normal cells and tumor cells, more research is needed, and not all The neurological disease medication can effectively inhibit tumor cells under the same conditions, and many problems need to be overcome.
  • Neurological drugs can be divided into six categories, namely Drugs used for pain relief, Psychotherapeutic drugs, Neurologic drugs, Drugs used in anesthesia, Antisympathy Parasympathomimetic (Cholinergic) Agents, and others.
  • the first major category pain relief agent Drugs used for pain relief
  • Non-steroidal anti-inflammatory agent external preparations 1. Topical non-steroidal anti-inflammatory ointment, limited to soft tissue rheumatism or arthritis patients who are not suitable for oral non-steroidal anti-inflammatory preparations, up to 40gm per month. 2.Flurbiprofen 40mg patch (such as Flur Di Fen Patch): For patients with the following conditions: (1) single joint (site) or soft tissue rheumatism. (2) Not suitable for oral non-steroidal anti-inflammatory preparations. (3) Oral or other topical non-steroidal inflammatory preparations may not be used at the same time. (4) Within sixteen prescriptions per month.
  • NSAIDs non-steroidal anti-inflammatory agents
  • NSAIDs non-steroidal anti-inflammatory agents
  • ketorolac ingredients (1) Patients who cannot be orally administered and cannot use an anal suppository use. (2) This class of drugs should not be used as a routine or long-term use of acute upper respiratory tract infections. (3) The use of this class of drugs, each time can not exceed five consecutive days.
  • Injection of Ketorolac ingredients It is limited to patients who cannot be taken orally and is short-term treatment for moderate to severe acute pain after surgery ( ⁇ 5 days during treatment), but it is forbidden to use in obstetrics.
  • Tramadol limit 1. Use of cancer cases. 2. For patients with non-cancer chronic intractable pain (pain period more than six months), the following conditions must be met: (1) Those who are unable to control pain or have serious side effects for taking NSAIDs. (2) A pain assessment report is required, which includes VAS and VRS (Visual Analogue Scale and Verbal Rating Scale) for pain intensity and pain relief.
  • VAS and VRS Visual Analogue Scale and Verbal Rating Scale
  • Tramadol HCl + acetaminophen (eg Ulltrace Tablets) is limited to patients with moderate to severe pain and is subject to the following conditions: 1. After treatment with other analgesics or non-steroidal anti-inflammatory drugs (NSAIDs) Unable to control pain or have serious side effects. 2. If the non-cancer patient is used for more than five days, the pain assessment report should be attached and evaluated every three months. The content should include VAS and VRS (Visual Analogue Scale and Verbal Rating Scale) for pain intensity and pain relief. .
  • VAS and VRS Visual Analogue Scale and Verbal Rating Scale
  • Non-steroidal anti-inflammatory agents drugs (such as celecoxib, nabumetone, meloxicam, etodolac, nimesulide) etoricoxib, naproxen and esomeprazole compound preparations: 1.
  • NSAIDs non-steroidal anti-inflammatory agents
  • the use of this type of preparation must meet one of the following conditions: 1) Osteoarthritis patients older than or equal to 60 years old. (2) Chronic inflammatory joint disease such as rheumatoid arthritis, ankylosing myelitis, and dry arthritis, which requires long-term use of non-steroidal anti-inflammatory agents. (3) Those with acute severe trauma, acute stroke and acute cardiovascular events. (4) Patients with adrenal steroids at the same time.
  • fibromyalgia (1) to meet the American College of Rheumatology (ACR) and clinical trials to test fibromyalgia diagnostic criteria: I. WPI (wide spread pain index) ⁇ 7, Symptom severity (SS) ⁇ 5 and pain rating scale ⁇ 6 points or WPI 3-6, SS scale ⁇ 9 and pain rating scale ⁇ 6 points. II. Symptoms last more than three months. III. Other disease factors should be excluded and detailed in the medical record.
  • the rheumatoid immunology department, the neurology department, the rehabilitation department and the pain specialists should not use the same medicines for the indications.
  • the pain rating scale is not reduced by 2 points or more after 3 months of use, the drug should be discontinued.
  • the medical record should be recorded every 3 months, and the maximum daily dose is 450mg.
  • the neurological disease of the present invention comprises Ketorolac (Toradol), Diclofenac, Dexmedetomidine HCl (Precedex), Acetanilide (Antifebrin), Diclofenac Diethylamine, Meptazinol HCl, Amidopyrine, Procaine (Novocaine) HCl, Bextra (valdecoxib), and the like.
  • Ketorolac Toradol
  • Diclofenac Dexmedetomidine HCl (Precedex)
  • Acetanilide Antifebrin
  • Diclofenac Diethylamine Meptazinol HCl
  • Amidopyrine Procaine (Novocaine) HCl
  • Bextra valdecoxib
  • the second major category Psychic drugs
  • SSRI serotonin reuptake inhibitors
  • SNRI serum stimulating hormone and norepinephrine reuptake inhibitors
  • other antidepressants fluvoxamine maleate, fluoxetine, paroxetine, sertraline, venlafaxine, milnacipran, Preparations such as mirtazapine, citalopram, escitalopram, duloxetine, agomelatine
  • the medical record should be clearly marked with the diagnosis basis and the reason for use.
  • Bupropion HCL Not paid as a smoking cessation treatment.
  • Second-generation antipsychotic drugs such as clozapine, olanzapine, risperidone, quetiapine, amisulpride, ziprasidone, aripiprazole, paliperidone, etc.:
  • the medical records should detail the patient's sleep disorders, make appropriate assessments and diagnoses, explore possible causes, and provide good sleep habits.
  • Non-psychiatrists and neurologists should not open more than one drug per day, and should not exceed 6 months during continuous treatment. If the condition requires long-term use, the medical record should indicate the cause, and if necessary, transfer to the psychiatric and neurologists to assess the appropriateness of their continued use.
  • Psychiatric and neurological specialists should provide a reasonable diagnosis for the case in which the drug must be used continuously, and record it in the medical record. 4. According to the general guidelines for use, it is not recommended to use a variety of sleeping pills. The sleeping pills should be prescribed according to the type of sleep disorder.
  • the records should be clearly defined and should be within a reasonable dose range. 5.
  • patients who have not established a stable medical relationship for the first time they are limited to prescription drugs for sleeping pills within 7 days.
  • 6.zaleplon ingredients for the treatment of insomnia patients who are difficult to fall asleep, only for severe, patient dysfunction or insomnia patients suffering from extreme stress the initial dose is 5mg per day for patients over 65 years of age.
  • the initial dose of eszopiclone ingredients for adult patients is 1 mg before bedtime, the highest dose is 3 mg before bedtime, and the highest dose for patients over 65 years old is 2 mg.
  • the neurological diseases of the present invention include Agomelatine, Amisulpride, Asenapine, Fluoxetine HCl, Fluvoxamine maleate, Granisetron HCl, Mianserin hydrochloride, Tianeptine sodium, Venlafaxine, Ziprasidone hydrochloride, Iloperidone (Fanapt), Risperidone (Risperdal), and Paliperidone.
  • the third category Neurologic drugs
  • Sodium valproate injection (eg Depakine Lyophilized Injection) is used in patients with epilepsy and is used in one of the following ways: 1. Patients who are ineffective or unable to tolerate phenytoin side effects and are unable to take valproic acid. 2. Patients with seizure clusters. 3. Patients with status epilepticus.
  • Gabapentin such as Neurontin
  • vigabatrin such as Sabril
  • tiagabine such as Gabitril
  • pregabalin such as Lyrica
  • zonisamide such as Zonegran
  • perampanel such as Fycompa
  • Topiramate (eg Topamax) is restricted to the following patients: 1. Limited to add on therapy for topical seizures that are not effectively controlled by other antiepileptic drugs or as a second line of monotherapy. 2. Treatment for the prevention of migraine (1) Migraine patients who meet the criteria for the diagnosis of migraine in the International Headache Association and who have any of the following conditions, and who have poor efficacy or can not tolerate side effects or have contraindications use. I. Even with acute drugs, recurrent migraine has seriously affected the daily life of patients. II. Special cases, such as hemiplegic migraine, basal migraine, prolonged yang before migraine or migraine infarction. III. Migraine attacks are frequent, 2 times or more per week. (2) When the daily therapeutic dose of Topiramate exceeds 100 mg, the reason for use should be clearly stated in the medical record.
  • General tablet capsules eg Keppra Film-Coated Tablets: (1) limited to add on therapy for topical seizures that are not effectively controlled by other antiepileptic drugs or as a second line of single drug therapy .
  • Sustained release tablet capsules such as UFree ER, Nobelin XR: Limited use for adjuvant treatment of partial seizures in patients over 16 years of age.
  • Oral solution such as Keppra Oral Solution: limited to the adjuvant treatment of local seizures that other antiepileptic drugs cannot effectively control.
  • Injections (such as Keppra concentrated infusion): for use in patients with epilepsy, and for one of the following: 1. Patients who are ineffective or unable to tolerate phenytoin injections and cannot take oral levetiracetam. 2. Patients with seizure clusters. 3. Patients with status epilepticus.
  • Epalon Tablets, NEPES Tablets, Nomi-Nox Tablets and other three drugs if due to side effects, need to switch to doepezil, rivastigmine or galantamine oral preparations of another drug, need to be approved before use.
  • MMSE Re-evaluate each year after use and follow the MMSE or CDR Smart Test. If the MMSE is reduced by 2 points (excluding) or the CDR is 1 level, the drug should be discontinued. Only three drugs, such as Epalon Tablets, NEPES Tablets, and Nomi-Nox Tablets, need to be re-evaluated every year after use to track MMSE or CDR smart tests. For example, MMSE is reduced by 2 points (excluding) or CDR regression 1 compared with the initial treatment. Level, then these drugs should be discontinued. Iv. Use rivastigmine slabs (such as Exelon Patch), limit one tablet per day, and do not use the same oral medication. II. Moderate to severe dementia: limited use of memantine oral preparations: i.
  • Smart test results are 10 ⁇ MMSE ⁇ 14 or CDR 2 grade patients.
  • Ii Patients who have used any of donepezil, rivastigmine, galantamine, if any of the above drugs are no longer applicable, and the MMSE or CDR smart test meets the standard (10 ⁇ MMSE ⁇ 14 or CDR 2), and After approval by the prior review, you will need to switch to memantine. However, memantine must not be used in combination with the three drugs mentioned in the preceding paragraph.
  • Iii Re-evaluate each year after use and follow the MMSE or CDR Smart Test. If the MMSE is reduced by 2 points (excluding) or the CDR is 1 level, the drug should be discontinued.
  • Severe dementia limited use of donepezil and memantine oral preparations: i. Smart test results for patients with MMSE 5-9 and CDR 3 grade. Ii. Those who are in bed or have no mobility should not use it. Iii. Those who have used memantine, donepezil, rivastigmine, galantamine and are no longer suitable, should not be used.
  • tracking MMSE smart test if the MMSE is reduced by 2 points (excluding) or more than the previous treatment, such drugs should be discontinued. Only five drugs, such as Epalon tablets, NEPES tablets, Nomi-Nox tablets, Ebixa tablets and Evy tablets, need to be re-evaluated every year after use, tracking MMSE smart test, such as MMSE less than 2 points when starting treatment (excluding) above, these drugs should be discontinued.
  • Dementia of Parkinson's disease limited neurology The physician diagnoses and prescribes the use of mild to moderate dementia. Limit use of rivastigmine oral preparations I. The results of the intelligent test are MMSE 10 to 26 or CDR 1 and 2 patients. II.
  • Dementia occurs at least one year after the diagnosis of Parkinson's disease. III. Each year after use, it needs to be re-evaluated to track the MMSE or CDR intelligent test. If the MMSE is reduced by 2 points (excluding) or the CDR is 1 step, the drug should be discontinued.
  • Start treatment definition refers to the score of the same group of drugs for the first time to apply for treatment
  • Parkinson's disease treatment drugs 1.3.4. Parkinson's disease treatment drugs:
  • a dopamine agonist (ropinirole, pramipexole, pergolide, lisuride, and rotigotine), or amantadine, or levodopa with a COMT inhibitor (entacapone: such as Comtan film) before or at the same time using levodopa -coated tab.
  • a dopamine agonist pramipexole, pergolide, lisuride, and rotigotine
  • Pramipexole and ropinirole for the treatment of primary leg dysfunction need to rule out renal failure, iron deficiency and multiple neuropathy, and should not be combined with dopamine agonist and levodopa.
  • the maximum daily dose of pramipexole is 0.75 mg.
  • the maximum daily dose of mopinirole is 4 mg.
  • Rotigotine tablets (such as Neupro Patch), limited to primary Parkinson's disease, limited to one tablet per day, and can not be combined with other dopamine agonist oral drugs
  • Attention deficit hyperactivity disorder treatment drug methylphenidate HCl sustained release dosage form such as Concerta Extended Release Tablets
  • atomoxetine HCl such as Strattera Hard capsules
  • Atomoxetine HCl should be used in a daily dose of more than 60mg. If the daily dose should exceed 60mg, the reason should be recorded in the medical record. You can use up to 2 capsules per day, and the maximum daily dose is 100mg.
  • MSLT report 5 Daytime excessive sleep scale, such as ESS, PDSS, SSS, etc.
  • the daily excess sleep symptom scale ESS, or PDSS, SSS was administered every 3-6 months after use to evaluate the efficacy.
  • Period of use After the first application is approved for 1 year, the MSLT examination should be re-examined to evaluate the objective effect, and the ESS or PDSS and SSS of the past 1 year should be attached at the same time. For two consecutive years of application, if the patient is highly compliant, and the efficacy is determined, it can be approved for 3 years. Otherwise, you still need to apply once a year. If one of the ESS or MSLT shows poor efficacy, you should stop using it. 7. Limit the maximum daily dose of 200mg.
  • the neurological disease drug of the present invention comprises Aprepitant (MK-0869), Rufinamide (Banzel), Felbamate, Levetiracetam, Oxcarbazepine, Rocuronium bromide, Vecuronium Bromide, Tizanidine HCl, Topiramate, Zonisamide, Naratriptan HCl, Rizatriptan Benzoate (in this category).
  • Maxalt Carbamazepine (Carbatrol), Levodopa (Sinemet), Methocarbamol (Robaxin), Atracurium besylate, Carbidopa, Tropisetron, Haloperidol (Haldol), Primidone (Mysoline), Pramipexole dihydrochloride monohydrate, Memantine HCl (Namenda), Duloxetine HCl (Cymbalta), Benserazide, Pramipexole (Mirapex), Entacapone, Atomoxetine HCl, Brinzolamide, Ropinirole HCl, Pergolide mesylate, Droperidol and Imipramine HCl.
  • the fourth category anesthetic Drugs used in anesthesia
  • Xylocaine (2% gel, 2% jelly): cases of artificial anal stoma in rectal surgery require regular insertion of a catheter or a vertebral deformity with a neurological dysfunction in children requiring long-term intermittent intermittent catheterization.
  • the neurological disease drug of the present invention comprises Etomidate, Pilocaine, Proparacaine HCl, Cisatracurium besylate (Nimbex), Bupivacaine hydrochloride (Marcain), Dexmedetomidine, Oxybuprocaine HCl and Butacaine in this category.
  • Radiation therapy for head and neck cancer patients (1) Subject: Radiation therapy for head and neck cancer patients with more than 26GY, causing dry mouth symptoms caused by decreased salivary function. (2) When to use: It is suitable for the symptoms of dry mouth caused by radiation therapy and after treatment. (3) Treatment period and assessment: After each use for two months, it is necessary to evaluate the symptom improvement scale after treatment with pilocarpine hydrochloride oral dosage form, and it is determined that those who have improved by 10 or more can continue to use it. (4) Dosage: Three to four times a day, one ingot (5mg/tablet, 5mg/tab) can be used as a dose adjustment reference. Remarks: The diagnostic criteria for the repair of Gram's syndrome are as follows: [The diagnostic criteria for Sjogren's syndrome are based on the European classification criteria established in 2002]
  • Subjective symptoms of the eye at least one of the following questions:
  • Oral subjective symptoms at least one of the following questions: (1) Do you feel that dry mouth symptoms persist for more than three months every day? (2) Is there a phenomenon of recurrent or persistent salivary gland enlargement in adulthood? (3) Do you often use fluids to help swallow dry food?
  • Autoimmune antibodies The following autoantibodies are present: (1) SSA or SSB or both. Synergistic Gram Judgment of group diagnostic criteria:
  • Primary repair granulosis no related diseases and need to meet the following conditions (1) or (2): (1) 4 of 6 conditions, including item 4 (histopathology) ) or item 6 (serum test) conditions are met. (2) Of the four objective conditions (ie, items 3, 4, 5, and 6), any three conditions are met.
  • Secondary granulomatosis The patient has a potentially related disease (eg, any clear connective tissue disease) and there is a condition 1 or 2 in the above diagnostic criteria, plus 3, 4, Any two of the five conditions, ie secondary granulosus syndrome.
  • a potentially related disease eg, any clear connective tissue disease
  • Subject of use It is required to meet the diagnostic criteria for the repair of Gram's syndrome.
  • Time of use Patients with primary or secondary granulose syndrome have dry mouth symptoms.
  • Treatment period and evaluation After half a year of use, the symptom improvement scale after ceviomeline hydrochloride treatment should be attached to the medical record to prove that cevimeline hydrochloride is effective and can continue to be used.
  • Dosage Three times a day, one (30mg/cap) per patient, can be used as a dose adjustment reference.
  • the neurological agent of the present invention comprises Biperiden HCl, Oxybutynin (Ditropan), Acetylcholine chloride, Bethanechol chloride, Pilocarpine HCl, Anisotropine Methylbromide, Physostigmine Salicylate and Procyclidine HCl in this category.
  • the sixth category other Miscellaneous
  • ALS/MND motor neuron disease
  • Hereditary motor neuron atrophy such as spinal muscular atrophy, etc.
  • juvenile long-term limb atrophy such as segmental or focal motor neuron disease, etc.
  • infectious neuronal diseases such as polio, etc.
  • focal dystonia such as torticollis, writing sputum, sacral muscle dysplasia, etc.
  • focal dystonia such as torticollis, writing sputum, sacral muscle dysplasia, etc.
  • the medical records must be treated in other ways for more than 6 months, and the patients with torticollis need to meet the Tsui's rating scale for cervical dystonia score of 11 or more.
  • the highest dose per injection 150 units of torticollis, 70 units of writing sputum and sacral muscle insufficiency, and the maximum number of injections 3 times a year.
  • Systemic dystonia is not covered. 3.
  • Age of treatment from the date of application: 2 to 10 years for the lower limbs and 2 to 12 years for the upper limbs.
  • Age of treatment from the date of application: 2 to 10 years for the lower limbs and 2 to 12 years for the upper limbs.
  • the same muscle part of the surgical treatment should not be injected. 4.
  • Used in adult arm after stroke (1) Limited to 20 years of age or older, after the occurrence of stroke, there are still arm shackles after rehabilitation, aids or medication for at least 6 months, affecting their daily activities (such as diet, For hygiene, dressing, etc., the degree of sputum is in accordance with the Modified Ashworth Scale assessment level 2 or 3, and the joint mobility (R1/R2) shows significant sputum, and excludes irreversible contracture of bed, arm contracture or joint fixation.
  • the injection is limited to two times a year. 6.
  • overactive bladder (1) adult patients diagnosed with idiopathic overactive bladder and having urinary incontinence (wet type) greater than 14 times per week, and Ineffective by at least one anticholinergic drug. (2) It needs to be used after prior review and approval. The recommended dose for each treatment is 100 units, which is limited to twice a year. The two injections need to be separated by more than three months, and the second use is limited to 6 after the first injection. Patients with a reduction in urinary incontinence frequency of more than 50% were evaluated at -12 weeks. (3) It is limited to diagnosis and implementation by urology specialist or obstetrician.
  • the pre-opening injection unit is only applicable to Dose calculation.
  • 1.6.2.2.Dysport Used in eyelids or half-faced sputum: (1) Limited to 12 years old or older, diagnosed as eyelid or half-faced by ophthalmology, neurology or pediatric neurologist at a teaching hospital above the district (including) The patient is used. (2) Those who need to meet the Spasm Intensity Scale level 3 or above, and those with a medical history of more than 6 months can apply for treatment. (3) The highest dose per injection: the eyelid is 80 units on each side, and the half-faced ridge is 120 units on each side. The principle of injecting up to 3 times a year is the principle. 2.
  • focal dystonia such as torticollis, writing sputum, sacral muscle dysplasia, etc.
  • focal dystonia such as torticollis, writing sputum, sacral muscle dysplasia, etc.
  • the medical records must be treated in other ways for more than 6 months, and the patients with torticollis need to meet the Tsui's rating scale for cervical dystonia score of 11 or more.
  • the highest dose per injection 600 units of torticollis, 280 units of written sputum and sacral muscle insufficiency, and the maximum number of injections 3 times a year.
  • Systemic dystonia is not covered.
  • Muscle tension is slightly increased and is manifested at the end of the joint's range of motion. 1+ muscle tension increased slightly, manifested in half of the joint activity. 2 Muscle tension increased significantly, manifested in the entire range of joint activity. 3 The muscle tension is more obviously increased, and the joint activity is difficult. 4 muscle tension is extremely high, no joint activity at all.
  • Solifenacin succinate such as Vesicare
  • mirabegron such as Betmiga
  • the neurological medications of the present invention include Vinblastine, Ramelteon (TAK-375), Aniracetam, Flumazenil, Lidocaine (Alphacaine), Mosapride citrate, Sumatriptan succinate, Varenicline tartrate, Riluzole (Rilutek), Allopurinol (Zyloprim), Zolmitriptan (Zomig), Isradipine (Dynacirc), Disulfiram (Antabuse), Divalproex sodium, Chlorpheniramine Maleate, Dapoxetine hydrochloride (Priligy), Nicotinamide (Niacinamide), Tropicamide, Pregnenolone, Alibendol, Irsogladine, Nefiracetam (Translon), Methscopolamine (Pamine), Meclizine 2HCl, Formoterol hemifumarate, Ketotifen fumarate (Zaditor), Ciprofloxacin (Cipro), Fenticonazole
  • the present invention provides a medicament for use in the preparation of an anticancer pharmaceutical composition, wherein the pharmaceutical composition is a medicament consisting of a drug selected from the group consisting of diseases of the nervous system.
  • the neurological disease drug is one or more selected from the group consisting of a pain reliever, a psychotherapeutic agent, a neuropharmaceutical, an anesthetic, and an antiseptic agent (Parasympathomimetic (Cholinergic) Agents).
  • the pain relieving agent comprises Ketorolac (Toradol), Diclofenac, Dexmedetomidine HCl (Precedex), Acetanilide (Antifebrin), Diclofenac Diethylamine, Meptazinol HCl, Amidopyrine, Procaine (Novocaine) HCl, Bextra (valdecoxib) One or more of Nefopam HCl and Pyrilamine Maleate.
  • Ketorolac Toradol
  • Diclofenac Dexmedetomidine HCl (Precedex)
  • Acetanilide Antifebrin
  • Diclofenac Diethylamine Meptazinol HCl
  • Amidopyrine Procaine (Novocaine) HCl
  • Bextra valdecoxib
  • the psychotherapeutic agent is selected from the group consisting of Agomelatine, Amisulpride, Asenapine, Fluoxetine HCl, Fluvoxamine maleate, Granisetron HCl, Mianserin hydrochloride, Tianeptine sodium, Venlafaxine, Ziprasidone hydrochloride, Iloperidone (Fanapt), Risperidone (Risperdal) ), Paliperidone (Invega), Quetiapine fumarate (Seroquel), Chlorprothixene, Aripiprazole (Abilify), Chlorpromazine (Sonazine), Lurasidone HCl, Azacyclonol, Reboxetine mesylate, Trifluoperazine 2HCl, Moclobemide, Loxapine Succinate, Droperidol, Penfluridol, Amoxapine, Serotonin HCl, One or more of Dibenzepine HC
  • the neuropharmaceutical is selected from the group consisting of Aprepitant (MK-0869), Rufinamide (Banzel), Felbamate, Levetiracetam, Oxcarbazepine, Rocuronium bromide, Vecuronium Bromide, Tizanidine HCl, Topiramate, Zonisamide, Naratriptan HCl, Rizatriptan Benzoate (Maxalt), Carbamazepine (Carbatrol), Levodopa (Sinemet), Methocarbamol (Robaxin), Atracurium besylate, Carbidopa, Tropisetron, Haloperidol (Haldol), Primidone (Mysoline), Pramipexole dihydrochloride monohydrate, Memantine HCl (Namenda), Duloxetine HCl ( Cymbalta), Benserazide, Pramipexole (Mirapex), Entacapone, Atomoxetine
  • the anesthetic comprises one or more of Etomidate, Pilocaine, Proparacaine HCl, Cisatracurium besylate (Nimbex), Bupivacaine hydrochloride (Marcain), Dexmedetomidine, Oxybuprocaine HCl and Butacaine.
  • the anticholinergic agent comprises one or more of Biperiden HCl, Oxybutynin (Ditropan), Acetylcholine chloride, Bethanechol chloride, Pilocarpine HCl, Anisotropine Methylbromide, Physostigmine Salicylate, and Procyclidine HCl.
  • the cancer is selected from one or more of the group consisting of lung cancer, intestinal cancer, colorectal cancer, prostate cancer, bladder cancer, cervical cancer, breast cancer, or skin cancer.
  • Fig. 1 shows the results of the application of the neurological disease of the present invention for inhibiting cancer cell analysis.
  • the original culture solution in the 96-well plate was aspirated, and a commercially available drug having a concentration of 10 uM and a volume of 100 ul was added to each well. After 72 hours, 100 ul of diluted WST-1 reagent was added to each well, and the dilution ratio was the culture solution and The volume ratio of the WST-1 stock solution is 9:1. Finally, the total volume of each well plate is 200 ul. Then, the 96-well plate is placed at 37 ° C for 30-90 minutes, using an elisa reader (ELISA) on the OD450. The absorbance values were detected and the survival rate of each cancer cell line was calculated. Neurological medication is used to inhibit cancer cell analysis results
  • Neurological medications are divided into five categories, (1) pain relievers, (2) psychotherapeutics, (3) neuropharmaceuticals, (4) anesthetics, and (5) antiseptic agents (Parasympathomimetic (Cholinergic) Agents).
  • Aprepitant (MK-0869) (Aprepitant (MK-0869)) has inhibitory effects on lung cancer, gastric cancer, skin cancer, and bladder cancer.
  • Agomelatine has inhibitory effects on lung cancer, gastric cancer, prostate cancer, bladder cancer, breast cancer, and blood cancer.
  • Vinblastine has inhibitory effects on lung cancer, gastric cancer, skin cancer, prostate cancer, bladder cancer, and blood cancer.
  • Rufinamide (Banzel) has inhibitory effects on lung cancer, gastric cancer, prostate cancer, and bladder cancer.
  • Ramelteon (TAK-375) has an inhibitory effect on lung cancer and bladder cancer.
  • Amisulpride has inhibitory effects on lung cancer, stomach cancer, prostate cancer, bladder cancer, and breast cancer.
  • Etomidate has an inhibitory effect on lung cancer.
  • Felbamate has an inhibitory effect on lung cancer, stomach cancer, rectal cancer and skin cancer.
  • Flumazenil inhibits lung cancer and rectal cancer.
  • Fluoxetine HCl has an inhibitory effect on lung cancer, gastric cancer, rectal cancer, skin cancer, and breast cancer.
  • Fluvoxamine maleate has an inhibitory effect on lung cancer, gastric cancer and bladder cancer.
  • Granisetron HCl has an inhibitory effect on lung cancer, gastric cancer, rectal cancer and skin cancer.
  • Levetiracetam has an inhibitory effect on lung cancer, liver cancer, rectal cancer and skin cancer.
  • Lidocaine (Alphacaine) has an inhibitory effect on lung cancer.
  • Mianserin hydrochloride has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, breast cancer and blood cancer.
  • Mosapride citrate has an inhibitory effect on lung cancer and skin cancer.
  • Oxcarbazepine has an inhibitory effect on lung cancer, stomach cancer and skin cancer.
  • Rocuronium bromide has an inhibitory effect on lung cancer, stomach cancer and skin cancer.
  • Vecuronium Bromide has an inhibitory effect on lung cancer, stomach cancer, skin cancer, bladder cancer, and breast cancer.
  • Sumatriptan succinate has inhibitory effects on lung cancer, stomach cancer and prostate cancer.
  • Tianeptine sodium has inhibitory effects on lung cancer, gastric cancer, rectal cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Tizanidine HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, breast cancer, and blood cancer.
  • Topiramate has inhibitory effects on lung cancer, stomach cancer, rectal cancer, skin cancer, prostate cancer and bladder cancer.
  • Varenicline tartrate has an inhibitory effect on lung cancer, stomach cancer, skin cancer and prostate cancer.
  • Venlafaxine has an inhibitory effect on lung cancer, stomach cancer, skin cancer and prostate cancer.
  • Naratriptan HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, breast cancer, and blood cancer.
  • Rizatriptan Benzoate (Maxalt) has an inhibitory effect on gastric cancer and bladder cancer.
  • Riluzole (Rilutek) has an inhibitory effect on bladder cancer and breast cancer.
  • Risperidone (Risperdal) has an inhibitory effect on lung cancer, gastric cancer and breast cancer.
  • Prilocaine has an inhibitory effect on lung cancer, bladder cancer, and breast cancer.
  • Allopurinol (Zyloprim) has an inhibitory effect on gastric cancer and breast cancer.
  • Ketorolac has inhibitory effects on lung cancer, gastric cancer, colon cancer, prostate cancer, bladder cancer, and breast cancer.
  • Zolmitriptan has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Isradipine (Dynacirc) has an inhibitory effect on gastric cancer.
  • Disulfiram (Antabuse) has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, breast cancer, and blood cancer.
  • Carbamazepine (Carbatrol) has an inhibitory effect on gastric cancer.
  • Divalproex sodium has an inhibitory effect on gastric cancer.
  • Paliperidone (Invega) has an inhibitory effect on lung cancer, gastric cancer, and breast cancer.
  • Methocarbamol (Robaxin) has an inhibitory effect on lung cancer, skin cancer, bladder cancer and breast cancer.
  • Oxybutynin (Ditropan) has an inhibitory effect on lung cancer, skin cancer, bladder cancer, and breast cancer.
  • Quetiapine fumarate has inhibitory effects on lung cancer, rectal cancer, skin cancer and breast cancer.
  • Chlorprothixene has inhibitory effects on lung cancer, gastric cancer, colon cancer, skin cancer and breast cancer.
  • Chlorpheniramine Maleate has an inhibitory effect on gastric cancer.
  • Atracurium besylate has an inhibitory effect on gastric cancer.
  • Dapoxetine hydrochloride (Priligy) has an inhibitory effect on gastric cancer.
  • Carbidopa has inhibitory effects on lung cancer, skin cancer, prostate cancer, and breast cancer.
  • Tropisetron has inhibitory effects on lung cancer, colon cancer, prostate cancer, and breast cancer.
  • Nicotinamide (Niacinamide) has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, bladder cancer, breast cancer, and blood cancer.
  • Diclofenac has an inhibitory effect on lung cancer, prostate cancer, and breast cancer.
  • Tropicamide has inhibitory effects on lung cancer, gastric cancer, skin cancer, prostate cancer, and breast cancer.
  • Pregnenolone has inhibitory effects on lung cancer, gastric cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Haloperidol has inhibitory effects on lung cancer, gastric cancer, colon cancer, prostate cancer, bladder cancer, and breast cancer.
  • Alibendol has inhibitory effects on lung cancer, stomach cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Irsogladine has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, bladder cancer, breast cancer, and blood cancer.
  • Nefiracetam (Translon) has an inhibitory effect on lung cancer.
  • Aripiprazole (Abilify) has inhibitory effects on lung cancer, rectal cancer, colon cancer, and prostate cancer.
  • Methscopolamine (Pamine) has an inhibitory effect.
  • Meclizine 2HCl has an inhibitory effect on lung cancer.
  • Pramipexole dihydrochloride monohydrate has an inhibitory effect on lung cancer and rectal cancer.
  • Formoterol hemifumarate has inhibitory effects on lung cancer, gastric cancer, and rectal cancer.
  • Ketotifen fumarate inhibits lung cancer and rectal cancer.
  • Ciprofloxacin (Cipro) has an inhibitory effect on gastric cancer and breast cancer.
  • Fenticonazole nitrate has inhibitory effects on gastric cancer and breast cancer.
  • Memantine HCl has inhibitory effects on lung cancer, colon cancer, prostate cancer, and breast cancer.
  • Cyproheptadine HCl (Periactin) has inhibitory effects on lung cancer, colon cancer, prostate cancer, and breast cancer.
  • Gimeracil has inhibitory effects on lung cancer, colon cancer, prostate cancer, and breast cancer.
  • Duloxetine HCl (Cymbalta) has inhibitory effects on gastric cancer, skin cancer, and bladder cancer.
  • Ivabradine HCl (Procoralan) has an inhibitory effect on gastric cancer.
  • Betaxolol (Betoptic) has an inhibitory effect on gastric cancer.
  • Ambrisentan has an inhibitory effect on gastric cancer.
  • Naltrexone HCl has an inhibitory effect on gastric cancer.
  • Levosulpiride (Levogastrol) has an inhibitory effect on gastric cancer.
  • Azasetron HCl (Y-25130) has an inhibitory effect on gastric cancer.
  • Lapatinib has inhibitory effects on lung cancer, gastric cancer, skin cancer, bladder cancer, breast cancer, and blood cancer.
  • Cisatracurium besylate (Nimbex) has an inhibitory effect on gastric cancer and skin cancer.
  • Dronedarone HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, breast cancer, and blood cancer.
  • Roflumilast (Daxas) has an inhibitory effect on gastric cancer, skin cancer, and bladder cancer.
  • Sitafloxacin hydrate has an inhibitory effect on gastric cancer and skin cancer.
  • Irinotecan HCl Trihydrate (Campto) has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, and bladder cancer.
  • Benserazide has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, and bladder cancer.
  • Bupivacainehydrochloride (Marcain) has inhibitory effects on gastric cancer, rectal cancer and colon cancer.
  • Bethanechol chloride has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, prostate cancer and bladder cancer.
  • Chlorpromazine (Sonazine) has inhibitory effects on lung cancer, gastric cancer, rectal cancer, bladder cancer, and breast cancer.
  • Clindamycin hydrochloride (Dalacin) has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Pramipexole has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Domperidone has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, bladder cancer, and breast cancer.
  • Estriol has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Maprotiline hydrochloride has inhibitory effects on gastric cancer, liver cancer, colon cancer, skin cancer and bladder cancer.
  • Ciclopirox (Penlac) has inhibitory effects on lung cancer, gastric cancer, rectal cancer, skin cancer, bladder cancer, and blood cancer.
  • Econazole nitrate (Spectazole) has an inhibitory effect on bladder cancer and blood cancer.
  • Miconazole (Monistat) has an inhibitory effect on lung cancer and blood cancer.
  • Acetanilide (Antifebrin) has an inhibitory effect on lung cancer.
  • Cefprozil hydrate (Cefzil) has an inhibitory effect on lung cancer and bladder cancer.
  • Tolterodine tartrate (Detrol LA) has an inhibitory effect on lung cancer and bladder cancer.
  • Azelastine hydrochloride (Astelin) has an inhibitory effect on lung cancer and bladder cancer.
  • 5-Aminolevulinic acid hydrochloride has an inhibitory effect on lung cancer and bladder cancer.
  • Clarithromycin (Biaxin, Klacid) has an inhibitory effect on lung cancer and bladder cancer.
  • Vancomycin HCl has inhibitory effects on lung cancer, colon cancer, prostate cancer, and bladder cancer.
  • Clobetasol propionate has an inhibitory effect on lung cancer, colon cancer, prostate cancer and bladder cancer.
  • Miglitol (Glyset) has an inhibitory effect on gastric cancer.
  • L-Thyroxine has an inhibitory effect on lung cancer.
  • Buflomedil HCl has an inhibitory effect on skin cancer.
  • PCI-32765 (Ibrutinib) has an inhibitory effect on lung cancer and skin cancer.
  • Amoxicillin (Amoxycillin) has an inhibitory effect on skin cancer.
  • Cabazitaxel (Jevtana) has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, and bladder cancer.
  • Niclosamide (Niclocide) has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, and blood cancer.
  • Lurasidone HCl has an inhibitory effect on lung cancer, gastric cancer and skin cancer.
  • Azilsartan (TAK-536) has an inhibitory effect on lung cancer, gastric cancer and skin cancer.
  • Palonosetron HCl has an inhibitory effect on lung cancer, gastric cancer, and skin cancer.
  • Azelnidipine has inhibitory effects on lung cancer, stomach cancer, liver cancer, rectal cancer and skin cancer.
  • Diclofenac Diethylamine has an inhibitory effect on lung cancer, gastric cancer and skin cancer.
  • Dexmedetomidine has an inhibitory effect on lung cancer, gastric cancer and skin cancer.
  • Atovaquone has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and blood cancer.
  • Etravirine (TMC125) has inhibitory effects on lung cancer, gastric cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and blood cancer.
  • Nadifloxacin has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, and bladder cancer.
  • Articaine HCl has an inhibitory effect on skin cancer.
  • Tylosin tartrate has an inhibitory effect on lung cancer.
  • Altrenogest has an inhibitory effect on lung cancer and rectal cancer.
  • Atomoxetine HCl has an inhibitory effect on rectal cancer.
  • Brinzolamide has an inhibitory effect on rectal cancer.
  • Ropinirole HCl has an inhibitory effect on rectal cancer and skin cancer.
  • Azlocillin sodium salt has an inhibitory effect on lung cancer and rectal cancer.
  • Azacyclonol has an inhibitory effect on lung cancer, rectal cancer and skin cancer.
  • Reboxetine mesylate has an inhibitory effect on rectal cancer and skin cancer.
  • Trifluoperazine 2HCl has inhibitory effects on gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and blood cancer.
  • Meptazinol HCl has an inhibitory effect on prostate cancer.
  • Fexofenadine HCl has an inhibitory effect on lung cancer, skin cancer and prostate cancer.
  • Amidopyrine has an inhibitory effect on prostate cancer.
  • Moclobemide has an inhibitory effect on gastric cancer and prostate cancer.
  • Pergolide mesylate has an inhibitory effect on prostate cancer.
  • Lithocholic acid has inhibitory effects on lung cancer, gastric cancer and prostate cancer.
  • Ethambutol HCl has an inhibitory effect on skin cancer and prostate cancer.
  • Acebutolol HCl has an inhibitory effect on rectal cancer, skin cancer, and prostate cancer.
  • Hyoscyamine (Daturine) has inhibitory effects on rectal cancer, skin cancer, and prostate cancer.
  • Ouabain has inhibitory effects on lung cancer, stomach cancer, rectal cancer, colon cancer, skin cancer, bladder cancer, prostate cancer, and blood cancer.
  • Procaine (Novocaine) HCl lung cancer, gastric cancer, prostate cancer, bladder cancer have inhibitory effects.
  • Hydroxyzine 2HCl has an inhibitory effect on lung cancer, gastric cancer, skin cancer, prostate cancer, and bladder cancer.
  • Flavoxate HCl has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, and prostate cancer.
  • Aclidinium Bromide has inhibitory effects on lung cancer, stomach cancer, liver cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, and bladder cancer.
  • Bismuth Subsalicylate has inhibitory effects on lung cancer, gastric cancer, rectal cancer, prostate cancer, and bladder cancer.
  • Diphemanil methylsulfate has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, and bladder cancer.
  • Doxapram HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, skin cancer, prostate cancer, and bladder cancer.
  • Methazolamide has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, and bladder cancer.
  • Norethindrone has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer and breast cancer.
  • Rumblemulin has an inhibitory effect on skin cancer.
  • Ronidazole has an inhibitory effect on colon cancer.
  • Hexamethonium bromide has an inhibitory effect on colon cancer, skin cancer and prostate cancer.
  • Decamethonium bromide has an inhibitory effect on prostate cancer.
  • Isovaleramide has an inhibitory effect on rectal cancer and breast cancer.
  • Penfluridol has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, breast cancer, and blood cancer.
  • D-Phenylalanine has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Benzethonium chloride has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, breast cancer, and blood cancer.
  • Cycelelate has an inhibitory effect on colon cancer.
  • Antazoline HCl has an inhibitory effect on lung cancer.
  • Azaperone has an inhibitory effect on lung cancer and breast cancer.
  • Oxybuprocaine HCl has an inhibitory effect on lung cancer and breast cancer.
  • Pilocarpine HCl has an inhibitory effect on lung cancer and breast cancer.
  • Zoxazolamine has an inhibitory effect on breast cancer.
  • Doxylamine Succinate has inhibitory effects on lung cancer, stomach cancer, colon cancer, skin cancer, prostate cancer and breast cancer.
  • Serotonin HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, bladder cancer, breast cancer, and blood cancer.
  • Anisotropine Methylbromide has an inhibitory effect on lung cancer, prostate cancer and breast cancer.
  • Bromocriptine Mesylate has inhibitory effects on lung cancer, stomach cancer, prostate cancer, and breast cancer.
  • Butacaine has inhibitory effects on lung cancer, colon cancer, prostate cancer, breast cancer, and blood cancer.
  • Dibenzepine HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Diphenylpyraline HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, colon cancer, skin cancer, prostate cancer, and breast cancer.
  • Nalmefene HCl has an inhibitory effect on skin cancer.
  • Oxethazaine has an inhibitory effect on lung cancer.
  • Physostigmine Salicylate has an inhibitory effect on skin cancer.
  • Pipenzolate Bromide has an inhibitory effect on skin cancer.
  • R-(-)-Apomorphine HCl Hemihydrate has an inhibitory effect on lung cancer, rectal cancer, colon cancer, skin cancer and bladder cancer.
  • Rhtopamine HCl has an inhibitory effect on lung cancer, skin cancer, and bladder cancer.
  • Terfenadine inhibits lung cancer, stomach cancer, liver cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, breast cancer, and blood cancer effect.
  • Tacrine HCl has an inhibitory effect on liver cancer, colon cancer, and skin cancer.
  • Pimozide has inhibitory effects on lung cancer, gastric cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Suxibuzone has an inhibitory effect on bladder cancer.
  • Triflupromazine HCl has an inhibitory effect on gastric cancer, rectal cancer, skin cancer, and bladder cancer.
  • Dicyclomine HCl has an inhibitory effect on lung cancer.
  • Thioridazine HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, rectal cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and breast cancer.
  • Imipramine HCl has an inhibitory effect on skin cancer, bladder cancer and breast cancer.
  • Nomifensine Maleate has an inhibitory effect on lung cancer, skin cancer and breast cancer.
  • Pyrilamine Maleate has an inhibitory effect on skin cancer, bladder cancer and breast cancer.
  • Diperodon HCl has inhibitory effects on lung cancer, gastric cancer, liver cancer, colon cancer, skin cancer, and breast cancer.
  • Prochlorperazine Dimaleate has inhibitory effects on lung cancer, gastric cancer, liver cancer, colon cancer, skin cancer, bladder cancer and breast cancer.
  • Quipazine Maleate has inhibitory effects on lung cancer, stomach cancer, liver cancer, colon cancer, skin cancer and breast cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

神经***疾病药物在制备抗癌医药组合物中的应用，所述神经***疾病药物选自疼痛解除剂、精神治疗剂、神经药物、麻醉剂、抗胆碱剂及其它药物中的一种或多种。

Description

神经***疾病用药在制备抗癌医药组合物中的应用 技术领域
本发明系为多种神经疾病用药的新适应症之应用，尤其该多种药物为通过临床实验且具有抑制多种癌症之用途。
背景技术
癌症长期高居全球死因之首，且罹患癌症人数更是逐年攀升，因此治疗癌症俨然成为重要的课题。癌症的治疗可区分为手术治疗、放射线治疗、化学治疗及标靶治疗。
一般来说，癌症药物治疗无论是化学治疗或标靶治疗，目的多是让癌细胞无法复制、***，来阻断肿瘤的蔓延扩张。在临床治疗选择上，通常会结合一到数种化疗药物以及标靶治疗，希望能藉由不同机制来杀死癌细胞以提高治疗效果，但事实上，还是常遇到患者对于治疗药物的反应不佳。进一步，许多癌细胞相继产生抗药性，使药物的使用成效大幅降低，最终导致癌症治疗失败。
发明人依据长年的研究经验，人类的癌症细胞常常有与正常细胞具有不同的表现性状，型态上的差异或是作用机转的变化或许也有可能被视为一种外来的侵入者，而每一种癌症细胞所在的位置不同，变异的状态又与所处的环境有关，因此，第一个提出使用神经疾病用药抑制癌症细胞的发明概念并且进行实验。
相对的，在这些已经使用数十年神经疾病用药，是早已被FDA所认可的用药，具有大量药物机转及人体研究成果数据，因此，若应用在癌症方面，这项新发展会更省时、减少成本，也能和其他治疗方式结合来提高效果。目前尚未有任何研究针对本发明所使用之药物，进行癌症治疗研究。
尽管如此，药物开发依然是重要的医学议题，必须经过繁复的临床前试验才能进入临床试验，根据统计，平均每一万个新药约只有五个能够进入第一期临床试验。此外，除了药物本身是否能大量制造的难题外，还需克服药物安全性、病人筛选、试用剂量等问题，即 便药物已经通过FDA的核准并上市，亦有可能因上市后于人体发现不良反应而强制下架回收，由此可见药物开发具有一定的困难程度。
发明内容
为解决上述的问题，本发明针对通过临床实验的多种药物进行新适应症的研发，而达到老药新用的目标。
经过实验设计结果显示神经疾病用药对正常细胞没有或仅有微小的毒性，但至于神经疾病用药在正常细胞与肿瘤细胞之间是否具有选择性的影响，还待更多的研究厘清，而且并非所有的神经疾病用药在相同的条件下均能有效的抑制肿瘤细胞，需要有许多的问题进行克服。
名词定义
神经***药物可分为六大类，分别为疼痛解除剂Drugs used for pain relief、精神治疗剂Psychotherapeutic drugs、神经药物Neurologic drugs、麻醉剂Drugs used in anesthesia、抗胆碱剂Parasympathomimetic(Cholinergic)Agents、其他。
第一大类:疼痛解除剂Drugs used for pain relief
1.1.1.非类固醇抗发炎剂外用制剂：1.外用非类固醇抗发炎软膏，限不适合口服非类固醇抗发炎制剂之软组织风湿症或关节炎病患使用，每月至多以处方40gm为限。2.Flurbiprofen 40mg patch(如Flur Di Fen Patch)：限同时符合下列条件之病患使用:(1)单一关节(部位)或软组织风湿症。(2)不适合口服非类固醇抗发炎制剂者。(3)不得同时并用口服或其他外用非类固醇发炎制剂。(4)每月限处方十六片以内。
1.1.2.非类固醇抗发炎剂(NSAIDs)之注射剂：1.非类固醇抗发炎剂(NSAIDs)之注射剂(ketorolac成分之注射剂除外)：(1)限不能口服，且不能使用***栓剂之病患使用。(2)本类药品不可作为急性上呼吸道感染之例行或长期性使用。(3)使用本类药品，每次不可连续超过五天。2.Ketorolac成分之注射剂：限用于无法口服之病人且为手术后中重度急性疼痛之短期治疗(治疗期间为≦5天)，惟禁止使用于产科止痛。
1.1.3.Tramadol限1.癌症病例使用。2.用于非癌症慢性顽固性疼痛(疼痛期超过六个月)之病人，需同时符合下述条件：(1)需为服用NSAIDs仍无法控制疼痛或有严重副作用者。 (2)需检附疼痛评估报告，内容需包括疼痛强度及疼痛缓解的VAS与VRS(Visual Analogue Scale和Verbal Rating Scale)。
1.1.4.Tramadol HCl+acetaminophen(如Ultracet Tablets)限用于中度至严重性疼痛之病人，需符合下述条件：1.经其他止痛药、或非类固醇抗发炎药物(NSAIDs)治疗后仍无法控制疼痛或有严重副作用者。2.非癌症病患使用超过五天时，需检附疼痛评估报告，并每隔三个月再评估乙次，内容需包括疼痛强度及疼痛缓解的VAS与VRS(Visual Analogue Scale和Verbal Rating Scale)。
1.1.5.非类固醇抗发炎剂(NSAIDs)药品(如celecoxib、nabumetone、meloxicam、etodolac、nimesulide)etoricoxib、含naproxen及esomeprazole复方制剂:1.本类制剂之使用需符合下列条件之一者：(1)年龄大于等于六十岁之骨关节炎病患。(2)类风湿性关节炎、僵直性脊髓炎、干癣性关节炎等慢性病发炎性关节病变，需长期使用非类固醇抗发炎剂者。(3)合并有急性严重创伤、急性中风及急性心血管事件者。(4)同时并有肾上腺类固醇之患者。(5)曾有消化性溃疡、上消化道出血或胃穿孔病史者。(6)同时并有抗拟血剂者。(7)肝硬化患者。2.使用本类制剂之病患不得预防性并用乙型组织胺受体阻断剂、氢离子帮浦阻断剂及其他消化性溃疡用药，亦不得合并使用***素剂(如misoprostol)3.Nimesulide限用于急性疼痛缓解，其连续处方不得超过15日。4.含naproxen及esomeprazole复方制剂不得作为急性疼痛的初始治疗。
1.1.6.Gabapentin、lidocaine贴片剂
限使用于带状疱疹皮肤病灶后神经痛，并符合下列条件：1.使用其他止痛剂或非类固醇抗发炎剂(NSAIDs)药品治疗后仍无法控制疼痛或有严重副作用者。2.Gabapentin成分口服制剂，限每日最大剂量为3,600mg，且日剂量超过2,400mg时，需于病历记载理由。临床症状改善，应逐步调低剂量。3.Lidocaine贴片剂(限使用Lidopat Patch)：(1)限每日最大剂量为3片，且日剂量超过2片时，需于病历记载理由。临床症状改善，应逐步调低剂量。限使用Lidopat Patch。(2)Lidopat贴片剂不得与gabapentin或pregabalin成分口服制剂并用。
1.1.7.Pregabalin
1.使用于带状疱疹皮肤病灶后神经痛，并符合下列条件：(1)经使用其他止痛剂或非类固醇抗发炎剂(NSAIDs)药品治疗后仍无法控制疼痛或有严重副作用者。(2)每日最大剂量为 600mg。2.使用于纤维肌痛(fibromyalgia)(1)需符合American College of Rheumatology(ACR)及临床试验实证纤维肌痛诊断标准：Ⅰ.WPI(wide spread pain index)≧7、Symptom severity(SS)≧5且pain rating scale≧6分或WPI 3-6、SS scale≧9且pain rating scale≧6分。Ⅱ.症状持续超过三个月。Ⅲ.应排除其他疾病因素，并于病历详载。(2)限风湿免疫科、神经内科、复健科及疼痛专科医师使用，不得并用同适应症之它类药品。(3)如使用3个月后pain rating scale未减少2分以上应予停药。(4)病历每3个月应记载一次评估结果，每日最大剂量为450mg。
1.1.8.Duloxetine(如Cymbalta)：
1.使用于糖尿病并发周边神经病变并具有临床神经疼痛(neuropathic pain)，且符合以下条件:(1)经神经科专科医师诊断或经神经传导(NCV)检查证实之多发性神经病变(polyneuropathy)(2)Pain rating scale≧4分。2.不得并用同类适应症之药品。3.使用后应每3个月评估一次，并于病历中记载评估结果，倘Pain rating scale较前一次评估之数值未改善或未持续改善，应予停止使用。4.每日最大剂量为60mg。
本发明中的神经疾病用药包含在本类别的有Ketorolac(Toradol)、Diclofenac、Dexmedetomidine HCl(Precedex)、Acetanilide(Antifebrin)、Diclofenac Diethylamine、Meptazinol HCl、Amidopyrine、Procaine(Novocaine)HCl、Bextra(valdecoxib)、Nefopam HCl及Pyrilamine Maleate中的一种或多种。
第二大类:精神治疗剂Psychotherapeutic drugs
1.2.1.选择性血清促进素再吸收抑制剂(SSRI)、血清促进素及正肾上腺素再吸收抑制剂(SNRI)及其他抗忧郁剂(fluvoxamine maleate、fluoxetine、paroxetine、sertraline、venlafaxine、milnacipran、mirtazapine、citalopram、escitalopram、duloxetine、agomelatine等制剂)：
使用时病历上应详细注明诊断依据及使用理由。
1.2.1.1.Bupropion HCL：作为戒烟治疗者不予给付。
1.2.2.抗精神病剂Antipsychotics
1.2.2.1.Clozapine(如Clozaril)
1.限精神科专科医师使用。2.前18周使用时，每周需作白血球检验，每次处方以七日为限，使用18周后，每月作一次白血球检验。3.申报费用时，应检附白血球检验报告。
1.2.2.2.Second generation antipsychotics(简称第二代抗精神病药品，如clozapine、olanzapine、risperidone、quetiapine、amisulpride、ziprasidone、aripiprazole、paliperidone等)：
1.本类制剂的使用需符合下列条件：(1)开始使用「第二代抗精神病药品」时需于病历记载：医疗理由或诊断，以及临床整体评估表(Clinical Global Impression，简称CGI)的分数。(2)经规则使用六至八周后，需整体评估其疗效，并于病历记载：临床整体评估表的分数。(3)日剂量超过下列治疗剂量时，需于病历记载理由：clozapine 400mg/天，risperidone 6mg/天，olanzapine 20mg/天，quetiapine 600mg/天，amisulpride 800mg/天，ziprasidone120mg/天，aripiprazole 15mg/天，paliperidone 12mg/天。2.本类药品不得使用于双极性疾患的郁症发作。3.Olanzapine用于预防双极性疾患复发时，限lithium、carbamazepine、valproate等药品至少使用两种以上，治疗无效或无法耐受副作用时使用。
1.2.3.Zaleplon、zolpidem、zopiclone及eszopiclone
1.使用***物，病历应详载病人发生睡眠障碍的情形，并作适当的评估和诊断，探讨可能的原因，并提供卫教建立良好睡眠习惯。2.非精神科医师、神经科专科医师若需开立本类药品，每日不宜超过一颗，连续治疗期间不宜超过6个月。若因病情需长期使用，病历应载明原因，必要时转精神科、神经科专科医师评估其继续使用的适当性。3.精神科、神经科专科医师应针对必须连续使用本药的个案，提出合理的诊断，并在病历上详细记录。4.依一般使用指引不建议各种***并用，应依睡眠障碍型态处方***，若需不同半衰期之药物并用应有明确之睡眠障碍型态描述纪录，且应在合理剂量范围内。5.对于首次就诊尚未建立稳定医病关系的病患，限处方7日内***管制药品。6.zaleplon成分药品用于治疗难以入睡的失眠病人，仅适用于严重，病人功能障碍或遭受极度压力的失眠症患者，用于65岁以上病患时，起始剂量为每日5mg。7.成人病患使用eszopiclone成分药品的起始剂量为睡前1mg，最高剂量为睡前3mg，65岁以上病患的最高剂量为2mg。
本发明中的神经疾病用药包含在本类别的有Agomelatine、Amisulpride、Asenapine、Fluoxetine HCl、Fluvoxamine maleate、Granisetron HCl、Mianserin hydrochloride、Tianeptine sodium、Venlafaxine、Ziprasidone hydrochloride、Iloperidone(Fanapt)、Risperidone(Risperdal)、Paliperidone(Invega)、Quetiapine fumarate(Seroquel)、Chlorprothixene、Aripiprazole(Abilify)、Chlorpromazine(Sonazine)、Lurasidone HCl、 Azacyclonol、Reboxetine mesylate、Trifluoperazine 2HCl、Moclobemide、Loxapine Succinate、Droperidol、Penfluridol、Amoxapine、Serotonin HCl、Dibenzepine HCl、Pimozide、Triflupromazine HCl、Thioridazine HCl、Imipramine HCl、Nomifensine Maleate及Prochlorperazine Dimaleate。
第三大类:神经药物Neurologic drugs
1.3.1.骨骼肌松弛剂Skeletal muscle relaxants
1.3.1.1.Tizanidine HCl(如Sirdalud tab)：
限下列病患使用1.神经***疾病引起痉挛症状之病例。2.急性疼痛性肌肉痉挛病例。
1.3.2.抗癫痫剂Antiepileptic drugs
1.3.2.1.Sodium valproate注射剂(如Depakine Lyophilized Injection)限癫痫症病患使用，且符合以下其中之一项者使用：1.对phenytoin注射剂无效或无法忍受phenytoin副作用且无法口服valproic acid的病患。2.癫痫连续发作(Seizure clusters)的病患。3.癫痫重积状态(Status epilepticus)的病患。
1.3.2.2.Gabapentin(如Neurontin)、vigabatrin(如Sabril)、tiagabine(如Gabitril)、pregabalin(如Lyrica)、zonisamide(如Zonegran)、perampanel(如Fycompa)：限用于其他抗癫痫药物无法有效控制的局部癫痫发作的辅助性治疗(add on therapy)。
1.3.2.3.Topiramate(如Topamax)限下列病患使用：1.限用于其他抗癫痫药物无法有效控制的局部癫痫发作之辅助治疗(add on therapy)或作为第二线的单一药物治疗。2.用于预防偏头痛的治疗(1)限符合国际头痛协会偏头痛诊断标准并有以下任一状况的偏头痛患者，且对现有预防药物疗效不佳或无法忍受副作用或有使用禁忌者使用。I.即使使用急性药物，反复发作偏头痛已严重影响到患者的日常生活。II.特殊病例，如偏瘫性偏头痛、基底性偏头痛、偏头痛之前预兆时间过长或是偏头痛梗塞等。Ⅲ.偏头痛发作频繁，每星期2次(含)以上。(2)Topiramate每日治疗剂量超过100mg时，需于病历详细记载使用理由。
1.3.2.4.Levetiracetam
1.一般锭剂胶囊剂(如Keppra Film-Coated Tablets)：(1)限用于其他抗癫痫药物无法有效控制的局部癫痫发作之辅助性治疗(add on therapy)或作为第二线的单一药物治疗。(2)十二岁以上青少年与成人病患的肌抽跃性癫痫发作的辅助治疗。2.缓释锭剂胶囊剂(如UFree  ER、Nobelin XR：限使用于十六岁以上病患之局部癫痫发作的辅助治疗。3.口服液剂(如Keppra Oral Solution)：限用于其他抗癫痫药物无法有效控制之局部癫痫发作的辅助性治疗。4.注射剂(如Keppra浓缩输注液)：限癫痫症病患使用，且符合以下其中之一项者使用：1.对phenytoin注射剂无效或无法忍受phenytoin副作用且无法口服levetiracetam的病患。2.癫痫连续发作(Seizure clusters)的病患。3.癫痫重积状态(Status epilepticus)的病患。
1.3.2.5.Lamotrigine(如Lamictal)
限下列病患使用：1.限用于其他抗癫痫药物无法有效控制的局部癫痫发作的辅助性治疗或作为第二线的单一药物治疗。2.限使用于18岁以上成人且为双极性疾患者，并依下列原则使用：(1)急性郁期:限使用于锂盐、carbamazepine、valproate药品治疗疗效不佳或治疗后由郁症转为躁症的个案。(2)双极性疾患之郁症预防:限使用于锂盐、carbamazepine、valproate药品治疗疗效不佳或无法耐受其副作用者，单纯用于躁症预防者不得使用。(3)日剂量超过200mg时，需于病历记载理由。
1.3.2.6Carbamazepine
1.使用于新病患：(1)处方使用carbamazepine成分药品之前，应先检查病患IC健保卡是否已注记曾检测带有HLA-B 1502基因，检测结果为阳性者，不得开立carbamazepine成分药品的处方。(2)医师欲为病患处方carbamazepine成分药品前，应先询问病患是否对该药品有过敏病史，若为不确认者或未检测者，宜先行作HLA-B 1502基因检测。2.使用于旧病患：若病患已服用4个月以上，且确认未曾出现喉咙痛、嘴巴破或皮肤症状(如分散的斑点或斑丘疹症状)等类似Steven-Johnson症候群或其他不良反应时，可依病情继续处方治疗，但仍需提醒病患注意上述症状之发生。3.医师为病患处方使用carbamazepine成分药品，以日剂药费申报者，应依规定详实申报处方明细。
1.3.3.失智症治疗药品
1.限用于依NINDS-ADRDA或DSM或ICD标准诊断为阿滋海默氏症或帕金森氏症的失智症病患。2.如有脑中风病史，临床诊断为「血管性失智症」，或有严重心脏传导阻断(heart block)的病患，不建议使用。3.需经事前审查核准后使用，第一次申请须检附以下数据：(1)CT、MRI或哈金斯氏量表(Hachinski lschemic Score)三项其中的任一结果报告。(2)CBC,VDRL,BUN,Creatinine,GOT,GPT,T4,TSH检验。(3)病历摘要。(4)MMSE或CDR智能测 验报告。4.依疾病别及严重度，另规定如下：(1)阿滋海默氏症的失智症，由神经科或精神科医师处方使用。Ⅰ.轻度至中度失智症：限使用donepezil、rivastigmine及galantamine口服制剂：i.智能测验结果为MMSE 10～26分或CDR 1级及2级之患者。ii.使用前述三种药品任一种后，三个月内，因副作用得换用本类另一种药物，不需另外送审，惟仍应于病历上记载换药理由。其中Epalon Tablets、NEPES Tablets、Nomi-Nox Tablets等3种药品，倘因副作用，需换用donepezil、rivastigmine或galantamine口服制剂的另一种药物，需另经事前审查核准后使用。iii.使用后每一年需重新评估，追踪MMSE或CDR智能测验，如MMSE较前一次治疗时减少2分(不含)以上或CDR退步1级，则应停用此类药品。惟Epalon Tablets、NEPES Tablets、Nomi-Nox Tablets等3种药品，使用后每一年需重新评估，追踪MMSE或CDR智能测验，如MMSE较起步治疗时减少2分(不含)以上或CDR退步1级，则应停用此类药品。iv.使用rivastigmine贴片剂(如Exelon Patch)，每日限用一片，且不得并用同成分的口服药品。Ⅱ.中重度失智症：限使用memantine口服制剂:i.智能测验结果为10≦MMSE≦14分或CDR 2级的患者。ii.曾使用过donepezil,rivastigmine,galantamine其中任一种药品的患者，若不再适用上述其中任一药物，且MMSE或CDR智能测验达标准(10≦MMSE≦14分或CDR 2级)，并经事前审查核准后得换用memantine。惟memantine不得与前项三种药品并用。iii.使用后每一年需重新评估，追踪MMSE或CDR智能测验，如MMSE较前一次治疗时减少2分(不含)以上或CDR退步1级，则应停用此类药品。惟Ebixa Tablets及Evy Tablets等2种药品，使用后每一年需重新评估，追踪MMSE或CDR智能测验，如MMSE较起步治疗时减少2分(不含)以上或CDR退步1级，则应停用此类药品。Ⅲ.重度失智症：限使用donepezil及memantine口服制剂:i.智能测验结果为MMSE 5-9分且CDR 3级的患者。ii.卧床或无行动能力者不得使用。iii.曾使用过memantine,donepezil,rivastigmine,galantamine而不再适用者，不得使用。
iv.donepezil及memantine二者不能并用。
v.使用后每一年需重新评估，追踪MMSE智能测验，如MMSE较前一次治疗时减少2分(不含)以上,则应停用此类药品。惟Epalon片剂、NEPES片剂、Nomi-Nox片剂、Ebixa片剂及Evy片剂等5种药品，使用后每一年需重新评估，追踪MMSE智能测验，如MMSE较起步治疗时减少2分(不含)以上，则应停用此类药品。(2)帕金森氏症的失智症:限神经科 医师诊断及处方使用于轻度至中度的失智症。限使用rivastigmine口服制剂Ⅰ.智能测验结果为MMSE 10～26分或CDR 1级及2级之患者。Ⅱ.失智症发生于帕金森氏症诊断至少一年以后。Ⅲ.使用后每一年需重新评估，追踪MMSE或CDR智能测验，如MMSE较前一次治疗时减少2分(不含)以上或CDR退步1级，则应停用此类药品。备注:起步治疗定义:系指同组药品第一次申请同意治疗的评分
1.3.4.帕金森氏症治疗药品：
1.如病人开始出现功能障碍，在使用levodopa之前或同时，得使用一种dopamine agonist(ropinirole、pramipexole、pergolide、lisuride及rotigotine)，或amantadine，或是levodopa并用COMT抑制剂(entacapone：如Comtan film-coated tab.)
2.Levodopa+carbidopa+entacapone三合一制剂(如Stalevo Film-Coated Tablets 150/37.5/200mg等3品项)：
限用于表现药效终期运动功能波动现象，以左多巴/多巴脱羧基脢抑制剂无法达到稳定治疗效果之巴金森氏症病人。
3.若已同时使用上述药物且达高剂量，仍无法达到满意的状态，或出现运动并发症(如异动症或肌强直)，需合并使用多类药物治疗时，应于病历上详细记载理由。
4.Rasagiline：
(1)可单独使用，每日最高剂量为1mg；或与levodopa并用，rasagiline每日最高剂量为0.5mg。(2)本品不得与levodopa以外之其他帕金森氏症治疗药品并用。
5.Pramipexole及ropinirole用于治疗原发性腿部躁动症时需先排除肾衰竭、铁缺乏症及多发性神经病变，且不得与dopamine agonist及levodopa并用。(1)pramipexole每日最大剂量为0.75mg。(2)ropinirole每日最大剂量为4mg。
6.Rotigotine贴片剂(如Neupro Patch)，限用于原发性帕金森氏症，每日限用一片，且不得并用其他dopamine agonist之口服药品
1.3.5.注意力不全过动症治疗药品methylphenidate HCl缓释剂型(如Concerta Extended Release Tablets)；atomoxetine HCl(如Strattera Hard capsules)(93/9/1、96/5/1、96/9/1、97/5/1)
1.限六岁至十八岁(含)，依DSM或ICD标准诊断为注意力不全过动症患者且对短效型methylphenidate(如Ritalin)治疗的副作用无法耐受，或治疗一个月以上，疗效不佳者使用， 并于病历上记载使用理由。2.如符合前项规定且已使用本类药品治疗半年以上，而十八岁后仍需服用者，需于病历上详细记载以往病史及使用理由。3.Atomoxetine HCl原则上每日限使用1粒，惟每日剂量需超过60mg时，应于病历中记载理由，则每日至多可使用2粒，每日最大剂量为100mg。
1.3.6.Modafinil(如Provigil Tablets 200mg)给付规定：同时需符合下列条件：1.限猝睡症(narcolepsy)患者有日间过度睡眠症状，且使用methylphenidate无效或无法忍受其副作用时使用。2.猝睡症之诊断需符2005年国际睡眠障碍分类标准(International Classification of Sleep Disorder II,ICSD II)，且夜间多频睡眠检查(nocturnal Polysomnography,PSG)和之后隔日之日间多次入睡睡眠检查(Multiple Sleep Latency Test,MSLT)需显示前一夜睡眠至少有6小时，MSLT之平均入睡潜伏期(sleep latency)需小于或等于8分钟，并需至少有两次或以上的入睡出现之快速动眼睡眠(Sleep-onset REM periods(SOREMP))。3.日间过度睡眠持续至少3个月以上，应有客观评估，如成人的爱普沃斯嗜睡量表ESS(Epworth sleepiness Scale)需高于9分，或儿童青少年日间嗜睡量表PDSS(Pediatric daytime sleepiness Scale)或史丹福嗜睡评量表SSS(Stanford sleepiness scale)，且需排除阻塞性睡眠呼吸障碍(obstructive sleep apnea)、周期性下肢抽动(Periodic leg movement disorder)和睡眠相位后移症候群(Delayed sleep phase syndrome)等造成日间过度睡眠之可能性。4.限有睡眠实验室之医院之神经内科、精神科、胸腔内科、耳鼻喉科专科医师使用。5.经事前审查核准后使用。首次申请时需检附以下数据：1.病历纪录2.ICSD II诊断3.PSG报告4.MSLT报告5.日间过度睡眠量表，如ESS、PDSS、SSS等。使用后每3-6个月施测日间过量睡眠症状量表ESS、或PDSS、SSS，以评估疗效。6.使用期程：第1次申请获准1年后，需重新进行MSLT检查以评估客观疗效，并同时检附过去1年之ESS或PDSS、SSS。连续2年申请，如病人服药顺从性高，且药效确定，则可每次核准3年。否则仍需每年申请1次，若ESS或MSLT其中之一显示疗效不佳，应即停用。7.限制每日最大剂量200mg。
本发明中的神经疾病用药包含在本类别的有Aprepitant(MK-0869)、Rufinamide(Banzel)、Felbamate、Levetiracetam、Oxcarbazepine、Rocuronium bromide、Vecuronium Bromide、Tizanidine HCl、Topiramate、Zonisamide、Naratriptan HCl、Rizatriptan Benzoate(Maxalt)、Carbamazepine(Carbatrol)、Levodopa(Sinemet)、Methocarbamol(Robaxin)、 Atracurium besylate、Carbidopa、Tropisetron、Haloperidol(Haldol)、Primidone(Mysoline)、Pramipexole dihydrochloride monohydrate、Memantine HCl(Namenda)、Duloxetine HCl(Cymbalta)、Benserazide、Pramipexole(Mirapex)、Entacapone、Atomoxetine HCl、Brinzolamide、Ropinirole HCl、Pergolide mesylate、Droperidol及Imipramine HCl。
第四大类:麻醉剂Drugs used in anesthesia
1.4.1.Propofol：
1.限使用人工呼吸器治疗且需要每日进行神智评估的病例使用。2.每次使用以不超过七十二小时为原则。3.不得作为例行性使用。
1.4.2.Cis-atracurium、atracurium：
1.限使用人工呼吸器治疗且肝或肾功能衰竭的病患使用。2.每次使用以不超过七十二小时为原则。3.不得作为例行性使用。
1.4.3.Vecuronium、rocuronium：
1.限使用人工呼吸器治疗之血液动力学不稳定的重症病患，且具有下述情形者：(1)心脏功能不稳定者。(2)心搏过速可能恶化者。2.每次使用以不超过七十二小时为原则。3.不得作为例行性使用。
1.4.4.局部麻醉剂(local anesthetics)
Xylocaine(2％凝胶剂，2％jelly)：限直肠外科人工***造口病例需居家定期***导管或脊椎畸型合并有神经功能障碍的病童需长期居家间歇导尿病例使用。
1.4.5.Dexmedetomidine(如Precedex Inj.)：
限用于短期可拔管的18岁以上外科病患，术后24小时内需镇静与止痛病患使用，且使用时间不得超过24小时。
本发明中的神经疾病用药包含在本类别的有Etomidate、Prilocaine、Proparacaine HCl、Cisatracurium besylate(Nimbex)、Bupivacaine hydrochloride(Marcain)、Dexmedetomidine、Oxybuprocaine HCl及Butacaine。
第五大类:Parasympathomimetic(Cholinergic)Agents
1.5.1.Pilocarpine hydrochloride口服剂型
1.使用于修格兰氏症候群(Sjogren's syndrome)病人：(1)使用对象：需符合修格兰氏症 候群的诊断标准。(2)使用时机：原发性或续发性修格兰氏症候群病人具有口干燥症状者。(3)治疗期程及评量：使用后每半年需检附pilocarpine hydrochloride口服剂型治疗后症状改善评量表于病历上，证明pilocarpine hydrochloride口服剂型治疗有效方可继续使用。(4)使用剂量：每日三至四次，每次一锭(5mg/tab)依病人反映，可做剂量调整参考。2.使用于头颈部癌放射线治疗病人(1)使用对象：头颈部癌放射线治疗超过26GY的患者，造成唾腺功能减低而引起的口干燥症状。(2)使用时机：适用于放射线治疗期间及治疗后所引起的口干燥症状需药物控制时。(3)治疗期程及评量：每使用两个月后，需以pilocarpine hydrochloride口服剂型治疗后症状改善评量表评估，认定确有改善者达10分(含)以上者方可继续使用。(4)使用剂量：每日三至四次，每次一锭(5mg/片，5mg/tab)依病人反应，可做剂量调整参考。备注：修格兰氏症候群的诊断标准如下：【修格兰氏症候群(Sjogren's syndrome)之诊断标准依据2002年修立之欧洲分类标准】
1.眼睛主观症状：至少符合下列问题之一：
(1)是否有每天，持续性，令人困扰的干眼症状持续三个月以上？(2)眼睛是否有反复性的异物感？(3)是否使用人工泪液一天大于三次？
2.口腔主观症状：至少符合下列问题之一：(1)是否每天都觉得口干症状持续三个月以上？(2)是否于成年后曾经有反复性或持续性唾液腺体肿大的现象？(3)是否经常使用流质来帮助吞食较干的食物？
3.眼睛客观表现：两项检查之中至少有一项呈阳性反应：(1)Shirmer's试验：在无麻醉下测试，5分钟后小于或等于5公厘。(2)Rose Bengal score或其他眼睛染色之评分，大于或等于4分(依据van Bijsterveld's评分***)。
4.组织病理学：在4mm2的唾液腺组织切片中显示腺体发炎而且≧1focus的淋巴球浸润(1Focus：≧50个淋巴球聚集)。
5.唾液腺的侵犯：下列检查之中至少有一项呈阳性反应：
(1)无刺激下唾液的分泌总量减少(15分钟少于1.5㏄)(2)腮腺唾液管X光照像呈现弥漫性唾液腺管扩大(呈像为斑点状，空洞状或不规则状)且无唾液管阻塞现象。(3)唾液腺闪烁造影检查呈现放射性同位元素之延迟显影，低浓度以及/或排出延迟。
6.自体免疫抗体：出现以下自体抗体：(1)SSA或SSB或两者皆有。合乎修格兰氏症候 群诊断标准之判定：
1.原发性修格兰氏症：无任何相关疾病且需合乎下述(1)或(2)项条件：(1)6项条件中4项符合，其中需有第4项(组织病理)或第6项(血清检查)条件符合。(2)4项客观条件(即第3、4、5、6项)中，任3项条件符合。
2.次发性修格兰氏症：患者有潜在相关疾病(例如：任何明确***疾病)而且存在有上述诊断标准中第1项条件，或第2条件，再加上第3、4、5项条件中任何2项，即考虑次发性修格兰氏症候群。
1.5.2.Cevimeline hydrochloride(如Evoxac Capsules)
1.使用对象：需符合修格兰氏症候群的诊断标准。2.使用时机：原发性或续发性修格兰氏症候群病人具有口干燥症状者。3.治疗期程及评量：使用后每半年需检附cevimeline hydrochloride治疗后症状改善评量表于病历上，证明cevimeline hydrochloride治疗有效方可继续使用。4.使用剂量：每日三次，每次一颗(30mg/cap)依病人反映，可做剂量调整参考。
本发明中的神经疾病用药包含在本类别的有Biperiden HCl、Oxybutynin(Ditropan)、Acetylcholine chloride、Bethanechol chloride、Pilocarpine HCl、Anisotropine Methylbromide、Physostigmine Salicylate及Procyclidine HCl。
第六大类:其他Miscellaneous
1.6.1.Riluzole(如Rilutek)
1.经两位神经科专科医师诊断为运动神经元疾病(ALS/MND)，且未气管切开或使用人工呼吸器的病患。2.遗传性运动神经元萎缩症(如spinal muscular atrophy等)，幼年性远程肢体萎缩症(如segmental or focal motor neuron disease等)，感染性神经元疾病(如polio等)不适用。
1.6.2.Botulinum toxin type A
本类药品限以下适应症使用，每一个案每一年需重新评估一次，惟用于成人中风后之手臂痉挛时，需经事前审查核准后使用(98/5/1)。
1.6.2.1.Botox
1.使用于眼睑痉挛或半面痉挛：(1)限12岁以上，经区域以上(含)教学医院之眼科、神经内科或小儿神经科专科医师诊断为眼睑痉挛或半面痉挛之病患使用。(2)需符合Spasm  Intensity Scale 3级(含)以上，另有病历记载病史6个月以上者可申请治疗。(3)每次注射最高剂量：眼睑痉挛为每侧20单位，半面痉挛为每侧30单位。每年最多注射3次为原则。2.使用于局部肌张力不全症(focal dystonia)(如斜颈、书写性痉挛、口颚部肌张力不全等)(1)限12岁以上，经区域以上(含)教学医院之神经内科、小儿神经科或复健科专科医师诊断为局部张力不全症之病患使用。(2)需有病历记载已持续以其他方式治疗6个月以上无效，且斜颈症者需符合Tsui’s rating scale for cervical dystonia分数11分(含)以上者。(3)每次注射最高剂量：斜颈症为150单位，书写性痉挛及口颚部肌张力不全为70单位，且每年最多注射3次为原则。(4)全身性肌张力不全症不在给付范围。3.使用于脑性麻痹病患:(1)限满2岁以上，经区域以上(含)教学医院复健科、神经内科或小儿神经科专科医师诊断为痉挛型脑性麻痹之病患使用。(2)其肢体之痉挛影响主动功能(如行走或手部动作)，该肢体之痉挛程度以Modified Ashworth Scale评估为2或3级，且经药物、复健或辅具治疗至少6个月以上无效者。(3)无固定不可逆之关节挛缩。(4)每次注射最高剂量每公斤体重12～15单位(总剂量不超过300单位)，下肢每块肌肉每公斤体重使用3～6单位，上肢每块肌肉每公斤体重使用1～2单位，且每年最多注射3次。(5)治疗年龄(以申请日期起计)：下肢为2～10岁，上肢为2～12岁。(6)经外科手术治疗之同肌肉部位不得再行注射。4.使用于成人中风后之手臂痉挛：(1)限20岁以上，中风发生后，经复健、辅具或药物治疗至少6个月以上仍有手臂痉挛，影响其日常活动(如饮食、卫生、穿衣等)者，痉挛程度符合Modified Ashworth Scale评估2或3级，且关节活动度(R1/R2)显示显著痉挛，并排除卧床、手臂挛缩或关节固定不可逆挛缩者。(2)限地区医院以上(含)神经内科或复健科专科医师诊断及注射。(3)每次注射最高剂量Botox 360单位，且每年最多3次。(4)需经事前审查核准后使用，申请时需检附病历数据、治疗计划及照片。(5)再次申请时需提出使用效果评估结果。(6)如因再次中风而导致卧床、手部肌肉挛缩或关节固定不可逆挛缩者，则应停用。5.使用于脊髓病变所引起的逼尿肌过动而导致尿失禁。(1)事前审查，每年附尿动力学审查，确诊为逼尿肌过动症。(2)18岁以上(含)之成人病患。(3)泌尿专科或神经内科或复健科医师诊断为因脊髓病变引发的逼尿肌过动症病患，由泌尿专科医师施行注射。(4)每周尿失禁次数至少14次。(5)病患需经至少一种抗胆碱药物治疗三个月无效(仍有明显逼尿肌过动症状)，或无法耐受抗胆碱药物副作用。(6)第1次注射后6-12周评估尿失禁频率改善未达50％者，不得再注射。(7)每次治 疗建议剂量200个单位，二次注射时间应间隔24周以上，且病患有治疗前症状(频尿、急尿与尿失禁)时再次注射，每年注射以两次为限。6.使用于膀胱过动症：(1)经尿路动力学检查诊断为原发性膀胱过动症(idiopathic overactive bladder)且有尿失禁(wet type)每周大于14次的成年患者，且经至少一种抗胆碱药物治疗无效。(2)需经事前审查核准后使用，每次治疗建议剂量为100单位，每年限用两次，两次注射时间需相隔三个月以上，且第二次使用限于第一次注射后在6-12周评估有尿失禁频率减少50％以上的患者。(3)限由泌尿专科或妇产科医师诊断及施行注射。
◎前开注射剂量单位仅适用于
Figure PCTCN2015092775-appb-000001
剂量计算。
1.6.2.2.Dysport 1.使用于眼睑痉挛或半面痉挛：(1)限12岁以上，经区域以上(含)教学医院之眼科、神经内科或小儿神经科专科医师诊断为眼睑痉挛或半面痉挛之病患使用。(2)需符合Spasm Intensity Scale 3级(含)以上，另有病历记载病史6个月以上者可申请治疗。(3)每次注射最高剂量：眼睑痉挛为每侧80单位，半面痉挛为每侧120单位。每年最多注射3次为原则。2.使用于局部肌张力不全症(focal dystonia)(如斜颈、书写性痉挛、口颚部肌张力不全等)(1)限12岁以上，经区域以上(含)教学医院之神经内科、小儿神经科或复健科专科医师诊断为局部张力不全症之病患使用。(2)需有病历记载已持续以其他方式治疗6个月以上无效，且斜颈症者需符合Tsui’s rating scale for cervical dystonia分数11分(含)以上者。(3)每次注射最高剂量：斜颈症为600单位，书写性痉挛及口颚部肌张力不全为280单位，且每年最多注射3次为原则。(4)全身性肌张力不全症不在给付范围。
3.使用于脑性麻痹病患(1)限满2岁以上，经区域以上(含)教学医院复健科、神经内科或小儿神经科专科医师诊断为痉挛型脑性麻痹之病患使用。(2)其肢体之痉挛影响主动功能(如行走或手部动作)，该肢体之痉挛程度以Modified Ashworth Scale评估为2或3级，且经药物、复健或辅具治疗至少6个月以上无效者。(3)无固定不可逆之关节挛缩。(4)每次注射最高剂量每公斤体重30单位(总剂量不超过900单位)，下肢每块肌肉每公斤体重使用9～18单位，上肢每块肌肉每公斤体重使用3～6单位，且每年最多注射3次。(5)治疗年龄(以申请日期起计)：下肢为2～10岁，上肢为2～12岁。(6)经外科手术治疗之同肌肉部位不得再行注射。
4.使用于成人中风后的手臂痉挛：(1)限20岁以上，中风发生后，经复健、辅具或药物 治疗至少6个月以上仍有手臂痉挛，影响其日常活动(如饮食、卫生、穿衣等)者，痉挛程度符合Modified Ashworth Scale评估2或3级，且关节活动度(R1/R2)显示显著痉挛，并排除卧床、手臂挛缩或关节固定不可逆挛缩者。(2)限地区医院以上(含)神经内科或复健科专科医师诊断及注射。(3)每次注射最高剂量Dysport 1000单位，且每年最多3次。(4)需经事前审查核准后使用，申请时需检附病历数据、治疗计划及照片。(5)再次申请时需提出使用效果评估结果。(6)如因再次中风而导致卧床、手部肌肉挛缩或关节固定不可逆挛缩者，则应停用。◎前开注射剂量单位仅适用于Dysport剂量计算。◎Spasm Intensity Scale：0正常眨眼次数。1、眨眼次数因对外界刺激(如光、风等)而增加。2、轻微但明显的眼睑震颤(无痉挛)，且未引起生活不便。3、中度，且极明显的眼睑痉挛，且引起生活不便。4、严重影响生活(无法阅读、驾驶等)。◎Modified Ashworth Scale：0无肌张力增加。1
肌肉张力轻微增加，表现在关节活动范围之末端。1+肌张力轻微增加，表现在关节活动一半范围之内。2肌肉张力明显增加，表现在整个关节活动范围内。3肌张力更明显增加，关节活动出现困难。4肌张力极高，无关节活动可言。
1.6.3.Tolterodine L-tartrate(如Detrusitol)；solifenacin succinate(如Vesicare)；mirabegron(如Betmiga):
1.限符合下列诊断标准条件之一者：(1)频尿：每天(24小时)排尿次数超过八次，并有详实病历纪录。(2)急尿：病患自述经常有一种很突然、很强烈想解尿的感觉。(3)急迫性尿失禁：对于尿急的感觉无法控制，并于24小时内至少也有一次漏尿的情形。
2.不宜使用本类药品者：(1)小儿夜尿。(2)单纯性应力性尿失禁。(3)膀胱逼尿肌无反射(detrusor areflexia)或膀胱不收缩所引起的排尿困难或尿失禁的症状。
3.Solifenacin succinate(如Vesicare)及mirabegron(如Betmiga)药品每天限使用1锭。
本发明中的神经疾病用药包含在本类别的有Vinblastine、Ramelteon(TAK-375)、Aniracetam、Flumazenil、Lidocaine(Alphacaine)、Mosapride citrate、Sumatriptan succinate、Varenicline tartrate、Riluzole(Rilutek)、Allopurinol(Zyloprim)、Zolmitriptan(Zomig)、Isradipine(Dynacirc)、Disulfiram(Antabuse)、Divalproex sodium、Chlorpheniramine Maleate、Dapoxetine hydrochloride(Priligy)、Nicotinamide(Niacinamide)、Tropicamide、Pregnenolone、Alibendol、Irsogladine、Nefiracetam (Translon)、Methscopolamine(Pamine)、Meclizine 2HCl、Formoterol hemifumarate、Ketotifen fumarate(Zaditor)、Ciprofloxacin(Cipro)、Fenticonazole nitrate、Cyproheptadine HCl(Periactin)、Gimeracil、Trimebutine、Ivabradine HCl(Procoralan)、Betaxolol(Betoptic)、Ambrisentan、Naltrexone HCl、Levosulpiride(Levogastrol)、Azasetron HCl(Y-25130)、Lapatinib、Dronedarone HCl(Multaq)、Fudosteine、Daxas、Sitafloxacin hydrate、Dabigatran etexilate,Pradaxa、Irinotecan HCl Trihydrate(Campto)、Clindamycin hydrochloride(Dalacin)、Domperidone(Motilium)、Estriol、Imatinib(Gleevec)、Nitrendipine、Olopatadine hydrochloride(Opatanol)、Pantothenic acid(pantothenate)、Sotalol(Betapace)、Maprotiline hydrochloride、Naphazoline hydrochloride(Naphcon)、Ciclopirox(Penlac)、Econazole nitrate(Spectazole)、Miconazole(Monistat)、Cefprozil hydrate(Cefzil)、Tolterodine tartrate(Detrol LA)、Azelastine hydrochloride(Astelin)、5-Aminolevulinic acid hydrochloride、Clarithromycin(Biaxin,Klacid)、Vancomycin HCl(Vancocin)、Clobetasol propionate、Miglitol(Glyset)、L-Thyroxine、Gliclazide(Diamicron)、Buflomedil HCl、PCI-32765(Ibrutinib)、Amoxicillin(Amoxycillin)、Cabazitaxel(Jevtana)、Niclosamide(Niclocide)、Azilsartan(TAK-536)、Palonosetron HCl、Azelnidipine、Atovaquone(Atavaquone)、Etravirine(TMC125)、Nadifloxacin、Oxybutynin chloride、Tripelennamine HCl、Ibandronate sodium、Articaine HCl、Butenafine HCl、Tylosin tartrate、Altrenogest、Azlocillin sodium salt、Fexofenadine HCl、Lithocholic acid、Ethambutol HCl、Acebutolol HCl、Hyoscyamine(Daturine)、Ouabain、Hydroxyzine 2HCl、Flavoxate HCl、Aclidinium Bromide、Bismuth Subsalicylate、Diphemanil methylsulfate、Doxapram HCl、Methazolamide、norethindrone、Pheniramine Maleate、Retapamulin、Ronidazole、Hexamethonium bromide、Decamethonium bromide、Aminosalicylate sodium、Sodium nitrite、Pramoxine HCl、Isovaleramide、D-Phenylalanine、Benzethonium chloride、Nicardipine HCl、Cyclandelate、Antazoline HCl、Tolperisone HCl、Azaperone、Zoxazolamine、Doxylamine Succinate、Bromocriptine Mesylate、Diphenylpyraline HCl、Physostigmine Hemisulfate Salt、Ethoxzolamide、Hemicholinium Bromide、Mesoridazine Besylate、Methapyrilene HCl、Nalmefene HCl、 Nialamide、Oxethazaine、Pipenzolate Bromide、R-(-)-Apomorphine HCl Hemihydrate、Ractopamine HCl、Terfenadine、Tacrine HCl、Suxibuzone、Nicotine Ditartrate、Dicyclomine HCl、Diperodon HCl、Quipazine Maleate及amine Maleate。
本发明提供一种神经***疾病用药在制备抗癌医药组合物中的应用，其中所述医药组合物是选自神经***疾病药物所组成的药物。
本发明一实施例中，其中所述神经***疾病药物是选自疼痛解除剂、精神治疗剂、神经药物、麻醉剂、抗胆碱剂(Parasympathomimetic(Cholinergic)Agents)中的一种或多种。
本发明一实施例中，其中所述疼痛解除剂包括Ketorolac(Toradol)、Diclofenac、Dexmedetomidine HCl(Precedex)、Acetanilide(Antifebrin)、Diclofenac Diethylamine、Meptazinol HCl、Amidopyrine、Procaine(Novocaine)HCl、Bextra(valdecoxib)、Nefopam HCl及Pyrilamine Maleate中的一种或多种。
本发明一实施例中，其中所述精神治疗剂是选自Agomelatine、Amisulpride、Asenapine、Fluoxetine HCl、Fluvoxamine maleate、Granisetron HCl、Mianserin hydrochloride、Tianeptine sodium、Venlafaxine、Ziprasidone hydrochloride、Iloperidone(Fanapt)、Risperidone(Risperdal)、Paliperidone(Invega)、Quetiapine fumarate(Seroquel)、Chlorprothixene、Aripiprazole(Abilify)、Chlorpromazine(Sonazine)、Lurasidone HCl、Azacyclonol、Reboxetine mesylate、Trifluoperazine 2HCl、Moclobemide、Loxapine Succinate、Droperidol、Penfluridol、Amoxapine、Serotonin HCl、Dibenzepine HCl、Pimozide、Triflupromazine HCl、Thioridazine HCl、Imipramine HCl、Nomifensine Maleate及Prochlorperazine Dimaleate中的一种或多种。
本发明一实施例中，其中所述神经药物是选自由Aprepitant(MK-0869)、Rufinamide(Banzel)、Felbamate、Levetiracetam、Oxcarbazepine、Rocuronium bromide、Vecuronium Bromide、Tizanidine HCl、Topiramate、Zonisamide、Naratriptan HCl、Rizatriptan Benzoate(Maxalt)、Carbamazepine(Carbatrol)、Levodopa(Sinemet)、Methocarbamol(Robaxin)、Atracurium besylate、Carbidopa、Tropisetron、Haloperidol(Haldol)、Primidone(Mysoline)、Pramipexole dihydrochloride monohydrate、Memantine HCl(Namenda)、Duloxetine HCl(Cymbalta)、Benserazide、Pramipexole(Mirapex)、Entacapone、Atomoxetine HCl、 Brinzolamide、Ropinirole HCl、Pergolide mesylate、Droperidol及Imipramine HCl中的一种或多种。
本发明一实施例中，其中所述麻醉剂包括Etomidate、Prilocaine、Proparacaine HCl、Cisatracurium besylate(Nimbex)、Bupivacaine hydrochloride(Marcain)、Dexmedetomidine、Oxybuprocaine HCl及Butacaine中的一种或多种。
本发明一实施例中，其中所述抗胆碱剂包括Biperiden HCl、Oxybutynin(Ditropan)、Acetylcholine chloride、Bethanechol chloride、Pilocarpine HCl、Anisotropine Methylbromide、Physostigmine Salicylate及Procyclidine HCl中的一种或多种。
本发明一实施例中，其中所述癌症系选自由肺癌、肠道癌、大肠直肠癌、***癌、膀胱癌、子***、乳癌或皮肤癌中的一种或多种。
附图说明
图1为本发明神经疾病用药应用于抑制癌细胞分析结果。
具体实施方式
建立细胞株
请参考表一，将不同癌症类型的细胞株进行继代培养，计算细胞数目后，将2×106细胞数置入培养皿，然后加入培养该细胞株的培养液补至体积为10ml，继续培养2-3天。之后将细胞计数，并分装至96孔盘，其中每孔的细胞数目固定为3000个细胞，且体积为100ul。
表一、细胞株及其培养所用的培养液
Figure PCTCN2015092775-appb-000002
Figure PCTCN2015092775-appb-000003
细胞存活分析方法
将96孔盘中原有的培养液吸掉，每孔加入浓度10uM、体积100ul的市售药物，放置72小时后，每孔再加入100ul已稀释的WST-1试剂，该稀释比例为培养液与WST-1原液的体积比为9：1，最后每个孔盘的总体积为200ul，然后将96孔盘放置于37℃，30～90分钟，利用elisa reader(酶联免疫检测仪)于OD450侦测吸光值，并计算各癌症细胞株的存活率。神经疾病用药应用于抑制癌细胞分析结果
神经疾病用药分为五大类，(1)疼痛解除剂、(2)精神治疗剂、(3)神经药物、(4)麻醉剂、(5)抗胆碱剂(Parasympathomimetic(Cholinergic)Agents)。
实验结果明显的显示有许多的神经疾病用药并无法有效的抑制癌症的细胞的生长(表二)。
表二、对癌症细胞株无抑制效果的神经疾病用药
原神经***疾病用药 抑制癌症细胞株数量
Aniracetam 0
Asenapine 0
Biperiden HCl 0
Ziprasidone hydrochloride 0
Zonisamide 0
Iloperidone(Fanapt) 0
Levodopa(Sinemet) 0
Acetylcholine chloride 0
Proparacaine HCl 0
Primidone(Mysoline) 0
Trimebutine 0
Dexmedetomidine HCl(Precedex) 0
BIBR 953(Dabigatran etexilate,Pradaxa) 0
Imatinib(Gleevec) 0
Nitrendipine 0
Olopatadine 0
hydrochloride(Opatanol) 0
Pantothenic acid(pantothenate) 0
Sotalol(Betapace) 0
Naphazoline hydrochloride(Naphcon) 0
Gliclazide(Diamicron) 0
Oxybutynin chloride 0
Tripelennamine HCl 0
Entacapone 0
Ibandronate sodium 0
Butenafine HCl 0
Pheniramine Maleate 0
Bextra(valdecoxib) 0
Aminosalicylate sodium 0
Sodium nitrite 0
Loxapine Succinate 0
Pramoxine HCl 0
Droperidol 0
Nefopam HCl 0
Nicardipine HCl 0
Tolperisone HCl 0
Amoxapine 0
Physostigmine Hemisulfate Salt 0
Ethoxzolamide 0
Hemicholinium Bromide 0
Mesoridazine Besylate 0
Methapyrilene HCl 0
Nialamide 0
Procyclidine HCl 0
Nicotine Ditartrate 0
Trimipramine Maleate 0
而相对的各种的神经疾病用药分子对于各种癌症细胞的抑制效果也不尽相同(图一)，经过发明人实验结果，证实神经疾病用药药物Aprepitant(MK-0869)(阿瑞吡坦(MK-0869)),Agomelatine(阿戈美拉汀),Vinblastine(长春碱),Rufinamide(Banzel)(卢非酰胺),Ramelteon(TAK-375)(雷美替胺),Amisulpride(氨磺必利),Etomidate(依托咪酯),Felbamate(非氨酯),Flumazenil(氟马西尼),Fluoxetine HCl(盐酸氟西汀),Fluvoxamine maleate (马来酸氟戊肟胺),Granisetron HCl(盐酸格拉司琼),Levetiracetam(左乙拉西坦),Lidocaine(Alphacaine)(利多卡因),Mianserin hydrochloride(盐酸米安舍林),Mosapride citrate(枸橼酸莫沙必利),Oxcarbazepine(奥卡西平),Rocuronium bromide(罗库溴铵),Vecuronium Bromide(维库溴铵),Sumatriptan succinate(琥珀酸舒马曲坦),Tianeptine sodium(噻萘普汀钠),Tizanidine HCl(盐酸替扎尼定),Topiramate(托佩马特),Varenicline tartrate(酒石酸伐尼克兰),Venlafaxine(文拉法辛),Naratriptan HCl(盐酸那拉曲坦),Rizatriptan Benzoate(Maxalt)(苯甲酸利扎曲坦),Riluzole(Rilutek)(利鲁唑),Risperidone(Risperdal)(利培酮),Prilocaine(丙胺卡因),Allopurinol(Zyloprim)(别嘌呤醇),Ketorolac(Toradol)(酮咯酸),Zolmitriptan(Zomig)(林可舒),Isradipine(Dynacirc)(伊拉地平),Disulfiram(Antabuse)(戒酒硫),Carbamazepine(Carbatrol)(卡马西平),Divalproex sodium(双丙戊酸钠),Paliperidone(Invega)(帕潘立酮),Methocarbamol(Robaxin)(美索巴莫),Oxybutynin(Ditropan)(奥昔布宁),Quetiapine fumarate(Seroquel)(富马酸喹硫平),Chlorprothixene(氯普硫蒽),Chlorpheniramine Maleate(扑尔敏),Atracurium besylate(卡肌宁),Dapoxetine hydrochloride(Priligy)(盐酸达泊西汀),Carbidopa(卡比多巴),Tropisetron(托烷司琼),Nicotinamide(Niacinamide)(烟碱),Diclofenac(双氯芬酸),Tropicamide(托吡卡胺),Pregnenolone(孕烯醇酮),Haloperidol(Haldol)(氟哌啶醇),Alibendol(烯丙柳胺醇),Irsogladine(伊索格拉定),Nefiracetam(Translon)(奈非西坦),Aripiprazole(Abilify)(阿立哌唑),Methscopolamine(Pamine)(甲基东莨菪碱),Meclizine 2HCl(盐酸美克洛嗪),Pramipexole dihydrochloride monohydrate(R-盐酸普拉克索),Formoterol hemifumarate(福莫特罗富马酸盐),Ketotifen fumarate(Zaditor)(富马酸酮替芬),Ciprofloxacin(Cipro)(环丙沙星),Fenticonazole nitrate(硝酸芬替康唑),Memantine HCl(Namenda)(盐酸美金刚),Cyproheptadine HCl(Periactin)(盐酸赛庚啶),Gimeracil(吉美嘧啶),Duloxetine HCl(Cymbalta)(盐酸度洛西汀),Ivabradine HCl(Procoralan)(盐酸伊伐布雷定),Betaxolol(Betoptic)(倍他洛尔),Ambrisentan(安立生坦),Naltrexone HCl(盐酸纳曲酮),Levosulpiride(Levogastrol)(左旋舒必利),Azasetron HCl(Y-25130)(盐酸阿扎司琼),Lapatinib(拉帕替尼),Cisatracurium besylate(Nimbex)(顺苯磺阿曲库铵),Dronedarone HCl(Multaq)(盐酸决奈达隆),Roflumilast(Daxas)(罗氟司特),Sitafloxacin  hydrate(西他沙星),Irinotecan HCl Trihydrate(Campto)(盐酸伊立替康),Benserazide(苄丝肼),Bupivacaine hydrochloride(Marcain)(盐酸布比卡因),Bethanechol chloride(氯贝胆碱),Chlorpromazine(Sonazine)(氯丙嗪),Clindamycin hydrochloride(Dalacin)(盐酸克林霉素),Pramipexole(Mirapex)(普拉克索),Domperidone(Motilium)(多潘立酮),Estriol(雌三醇),Maprotiline hydrochloride(盐酸马普替林),Ciclopirox(Penlac)(环吡酮胺(Penlac)),Econazole nitrate(Spectazole)(硝酸益康唑),Miconazole(Monistat)(咪康唑),Acetanilide(Antifebrin)(乙酰苯胺),Cefprozil hydrate(Cefzil)(头孢丙烯),Tolterodine tartrate(Detrol LA)(酒石酸托特罗定),Azelastine hydrochloride(Astelin)(氮卓斯汀盐酸盐),5-Aminolevulinic acid hydrochloride(5-氨基乙酰丙酸盐酸盐),Clarithromycin(Biaxin,Klacid)(克拉霉素),Vancomycin HCl(Vancocin)(盐酸万古霉素),Clobetasol propionate(丙酸氯倍他索),Miglitol(Glyset)(米格列醇),L-Thyroxine(L-甲状腺素),Buflomedil HCl(盐酸丁咯地尔),PCI-32765(Ibrutinib)(布鲁顿酪氨酸激酶抑制剂),Amoxicillin(Amoxycillin)(阿莫西林),Cabazitaxel(Jevtana)(卡巴他赛),Niclosamide(Niclocide)(氯硝柳胺),Lurasidone HCl(盐酸鲁拉西酮),Azilsartan(TAK-536)(阿齐沙坦),Palonosetron HCl(盐酸帕洛诺司琼),Azelnidipine(阿折地平),Diclofenac(双氯芬酸)Diethylamine(二乙胺),Dexmedetomidine(右旋美托咪啶),Atovaquone(Atavaquone)(阿托伐醌),Etravirine(TMC125)(依曲韦林),Nadifloxacin(那氟沙星),Articaine HCl阿替卡因),Tylosin tartrate(酒石酸太乐菌素),Altrenogest(四烯雌酮),Atomoxetine HCl(盐酸阿托西汀),Brinzolamide(布林佐胺),Ropinirole HCl(盐酸罗匹尼罗),Azlocillin sodium salt(？),Azacyclonol(阿扎环醇),Reboxetine mesylate(甲磺酸瑞波西汀),Trifluoperazine 2HCl(盐酸三氟拉嗪),Meptazinol HCl(盐酸美普他酚),Fexofenadine HCl(盐酸非索非那定),Amidopyrine(氨基比林),Moclobemide(吗氯贝胺),Pergolide mesylate(甲磺酸培高利特),Lithocholic acid(石胆酸),Ethambutol HCl(盐酸乙胺丁醇),Acebutolol HCl(盐酸艾思布妥),Hyoscyamine(Daturine)(莨菪碱),Ouabain(乌本苷),Procaine(Novocaine)HCl(盐酸普鲁卡因),Hydroxyzine 2HCl(盐酸羟嗪),Flavoxate HCl(盐酸黄酮哌酯),Aclidinium Bromide(阿地溴铵),Bismuth Subsalicylate(碱式水杨酸铋),Diphemanil methylsulfate(二苯马尼甲硫酸盐),Doxapram HCl(盐酸多沙普仑),Methazolamide(美舍唑咪),Norethindrone (焕诺酮),Retapamulin(瑞他莫林),Ronidazole(罗硝唑),Hexamethonium bromide(溴化六甲铵),Decamethonium bromide(溴化十烃季胺),Isovaleramide(异戊酰胺),Penfluridol(五氟利多),D-Phenylalanine(D-苯丙氨酸),Benzethonium chloride(苄索氯铵),Cyclandelate(抗栓丸),Antazoline HCl(盐酸安他唑啉),Azaperone(阿扎哌隆),Oxybuprocaine HCl(盐酸丁氧普鲁卡因),Pilocarpine HCl(盐酸毛果芸香碱),Zoxazolamine(氯苯恶唑胺),Doxylamine Succinate(多西拉敏),Serotonin HCl(5-羟基色胺盐酸盐),Anisotropine(辛托品)Methylbromide(溴甲烷),Bromocriptine Mesylate(溴隐亭甲烷磺酸盐),Butacaine(布他卡因),Dibenzepine HCl(盐酸二苯西平),Diphenylpyraline HCl(盐酸双苯比拉林),Nalmefene HCl(纳美芬),Oxethazaine(奥昔卡因),Physostigmine(毒扁豆碱)Salicylate(水杨酸钠),Pipenzolate Bromide(吡哌喷酯),R-(-)-Apomorphine HCl Hemihydrate(阿朴***半水化合物),Ractopamine HCl(盐酸莱克多巴胺),Terfenadine(特非那定),Tacrine HCl(盐酸他克林),Pimozide(哌迷清),Suxibuzone(琥保松),Triflupromazine HCl(盐酸三氟丙嗪),Dicyclomine HCl(盐酸双环胺),Thioridazine HCl(盐酸硫利达嗪),Imipramine HCl(丙咪嗪),Nomifensine Maleate(马来酸诺米芬新),Pyrilamine Maleate(马来酸吡拉明),Diperodon HCl(盐酸地哌冬),Prochlorperazine Dimaleate(马来酸丙氯拉嗪),Quipazine Maleate(马来酸喹哌嗪)等药物对于不同的癌症细胞有明显的抑制效果。(表三)
重复性实验
依据表三所示结果，针对对癌症细胞株有效之药物进行重复性实验，其结果如表四所示。
Figure PCTCN2015092775-appb-000004
Figure PCTCN2015092775-appb-000005
Figure PCTCN2015092775-appb-000006
Figure PCTCN2015092775-appb-000007
Figure PCTCN2015092775-appb-000008
Figure PCTCN2015092775-appb-000009
Figure PCTCN2015092775-appb-000010
Figure PCTCN2015092775-appb-000011
Figure PCTCN2015092775-appb-000012
Figure PCTCN2015092775-appb-000013
Figure PCTCN2015092775-appb-000014
Figure PCTCN2015092775-appb-000015
Figure PCTCN2015092775-appb-000016
Figure PCTCN2015092775-appb-000017
Figure PCTCN2015092775-appb-000018
Figure PCTCN2015092775-appb-000019
Figure PCTCN2015092775-appb-000020
Figure PCTCN2015092775-appb-000021
Aprepitant(MK-0869)(阿瑞吡坦(MK-0869))对肺癌,胃癌,皮肤癌,膀胱癌有抑制效果。
Agomelatine(阿戈美拉汀)对肺癌,胃癌,,***癌,膀胱癌,乳癌,血癌有抑制效果。
Vinblastine(长春花碱)对肺癌,胃癌,皮肤癌,***癌,膀胱癌,血癌有抑制效果。
Rufinamide(Banzel)对肺癌,胃癌,***癌,膀胱癌有抑制效果。
Ramelteon(TAK-375)对肺癌,膀胱癌有抑制效果。
Amisulpride对肺癌,胃癌,***癌,膀胱癌,乳癌有抑制效果。
Etomidate对肺癌有抑制效果。
Felbamate对肺癌,胃癌,直肠癌,皮肤癌有抑制效果。
Flumazenil对肺癌,直肠癌抑制效果。
Fluoxetine HCl对肺癌,胃癌,直肠癌,皮肤癌,乳癌有抑制效果。
Fluvoxamine maleate对肺癌,胃癌,膀胱癌有抑制效果。
Granisetron HCl对肺癌,胃癌,直肠癌,皮肤癌有抑制效果。
Levetiracetam对肺癌,肝癌,直肠癌,皮肤癌有抑制效果。
Lidocaine(Alphacaine)对肺癌有抑制效果。
Mianserin hydrochloride对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,血癌有抑制效果。
Mosapride citrate对肺癌,皮肤癌有抑制效果。
Oxcarbazepine对肺癌,胃癌,皮肤癌有抑制效果。
Rocuronium bromide对肺癌,胃癌,皮肤癌有抑制效果。
Vecuronium Bromide对肺癌,胃癌,皮肤癌,膀胱癌,乳癌有抑制效果。
Sumatriptan succinate对肺癌,胃癌,***癌有抑制效果。
Tianeptine sodium对肺癌,胃癌,直肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Tizanidine HCl对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,血癌有抑制效果。
Topiramate对肺癌,胃癌,直肠癌,皮肤癌,***癌,膀胱癌有抑制效果。
Varenicline tartrate对肺癌,胃癌,皮肤癌,***癌有抑制效果。
Venlafaxine对肺癌,胃癌,皮肤癌,***癌有抑制效果。
Naratriptan HCl对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,血癌有抑制效果。
Rizatriptan Benzoate(Maxalt)对胃癌,膀胱癌有抑制效果。
Riluzole(Rilutek)对膀胱癌,乳癌有抑制效果。
Risperidone(Risperdal)对肺癌,胃癌,乳癌有抑制效果。
Prilocaine对肺癌,膀胱癌,乳癌有抑制效果。
Allopurinol(Zyloprim)对胃癌,乳癌有抑制效果。
Ketorolac(Toradol)对肺癌,胃癌,结肠癌,***癌,膀胱癌,乳癌有抑制效果。
Zolmitriptan(Zomig)对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Isradipine(Dynacirc)对胃癌有抑制效果。
Disulfiram(Antabuse)对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,乳癌,血癌有抑制效果。
Carbamazepine(Carbatrol)对胃癌有抑制效果。
Divalproex sodium对胃癌有抑制效果。
Paliperidone(Invega)对肺癌,胃癌,乳癌有抑制效果。
Methocarbamol(Robaxin)对肺癌,皮肤癌,膀胱癌,乳癌有抑制效果。
Oxybutynin(Ditropan)对肺癌,皮肤癌,膀胱癌,乳癌有抑制效果。
Quetiapine fumarate(Seroquel)对肺癌,直肠癌,皮肤癌,乳癌有抑制效果。
Chlorprothixene对肺癌,胃癌,结肠癌,皮肤癌,乳癌有抑制效果。
Chlorpheniramine Maleate对胃癌有抑制效果。
Atracurium besylate对胃癌有抑制效果。
Dapoxetine hydrochloride(Priligy)对胃癌有抑制效果。
Carbidopa对肺癌,皮肤癌,***癌,乳癌有抑制效果。
Tropisetron对肺癌,结肠癌,***癌,乳癌有抑制效果。
Nicotinamide(Niacinamide)对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,膀胱癌,乳癌,血癌有抑制效果。
Diclofenac对肺癌,***癌,乳癌有抑制效果。
Tropicamide对肺癌,胃癌,皮肤癌,***癌,乳癌有抑制效果。
Pregnenolone对肺癌,胃癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Haloperidol(Haldol)对肺癌,胃癌,结肠癌,***癌,膀胱癌,乳癌有抑制效果。
Alibendol对肺癌,胃癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Irsogladine对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,膀胱癌,乳癌,血癌有抑制效果。
Nefiracetam(Translon)对肺癌有抑制效果。
Aripiprazole(Abilify)对肺癌,直肠癌,结肠癌,***癌有抑制效果。
Methscopolamine(Pamine)对抑制效果。
Meclizine 2HCl对肺癌有抑制效果。
Pramipexole dihydrochloride monohydrate对肺癌,直肠癌有抑制效果。
Formoterol hemifumarate对肺癌,胃癌,直肠癌有抑制效果。
Ketotifen fumarate(Zaditor)对肺癌,直肠癌抑制效果。
Ciprofloxacin(Cipro)对胃癌,乳癌有抑制效果。
Fenticonazole nitrate对胃癌,乳癌有抑制效果。
Memantine HCl(Namenda)对肺癌,结肠癌,***癌,乳癌有抑制效果。
Cyproheptadine HCl(Periactin)对肺癌,结肠癌,***癌,乳癌有抑制效果。
Gimeracil对肺癌,结肠癌,***癌,乳癌有抑制效果。
Duloxetine HCl(Cymbalta)对胃癌,皮肤癌,膀胱癌有抑制效果。
Ivabradine HCl(Procoralan)对胃癌有抑制效果。
Betaxolol(Betoptic)对胃癌有抑制效果。
Ambrisentan对胃癌有抑制效果。
Naltrexone HCl对胃癌有抑制效果。
Levosulpiride(Levogastrol)对胃癌有抑制效果。
Azasetron HCl(Y-25130)对胃癌有抑制效果。
Lapatinib对肺癌,胃癌,皮肤癌,膀胱癌,乳癌,血癌有抑制效果。
Cisatracurium besylate(Nimbex)对胃癌,皮肤癌有抑制效果。
Dronedarone HCl(Multaq)对肺癌,胃癌,肝癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,血癌有抑制效果。
Roflumilast(Daxas)对胃癌,皮肤癌,膀胱癌有抑制效果。
Sitafloxacin hydrate对胃癌,皮肤癌有抑制效果。
Irinotecan HCl Trihydrate(Campto)对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌有抑制效果。
Benserazide对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌有抑制效果。
Bupivacainehydrochloride(Marcain)对胃癌,直肠癌,结肠癌有抑制效果。
Bethanechol chloride对肺癌,胃癌,肝癌,直肠癌,***癌,膀胱癌有抑制效果。
Chlorpromazine(Sonazine)对肺癌,胃癌,直肠癌,膀胱癌,乳癌有抑制效果。
Clindamycin hydrochloride(Dalacin)对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Pramipexole(Mirapex)对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Domperidone(Motilium)对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,膀胱癌,乳癌有抑制效果。
Estriol对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,有抑制效果。
Maprotiline hydrochloride对胃癌,肝癌,结肠癌,皮肤癌,膀胱癌有抑制效果。
Ciclopirox(Penlac)对肺癌,胃癌,直肠癌,皮肤癌,膀胱癌,血癌有抑制效果。
Econazole nitrate(Spectazole)对膀胱癌,血癌有抑制效果。
Miconazole(Monistat)对肺癌,血癌有抑制效果。
Acetanilide(Antifebrin)对肺癌有抑制效果。
Cefprozil hydrate(Cefzil)对肺癌,膀胱癌有抑制效果。
Tolterodine tartrate(Detrol LA)对肺癌,膀胱癌有抑制效果。
Azelastine hydrochloride(Astelin)对肺癌,膀胱癌有抑制效果。
5-Aminolevulinic acid hydrochloride对肺癌,膀胱癌有抑制效果。
Clarithromycin(Biaxin,Klacid)对肺癌,膀胱癌有抑制效果。
Vancomycin HCl(Vancocin)对肺癌,结肠癌,***癌,膀胱癌有抑制效果。
Clobetasol propionate对肺癌,结肠癌,***癌,膀胱癌有抑制效果。
Miglitol(Glyset)对胃癌有抑制效果。
L-Thyroxine对肺癌有抑制效果。
Buflomedil HCl对皮肤癌有抑制效果。
PCI-32765(Ibrutinib)对肺癌,皮肤癌有抑制效果。
Amoxicillin(Amoxycillin)皮肤癌有抑制效果。
Cabazitaxel(Jevtana)对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,膀胱癌有抑制效果。
Niclosamide(Niclocide)对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,血癌有抑制效果。
Lurasidone HCl对肺癌,胃癌,皮肤癌有抑制效果。
Azilsartan(TAK-536)对肺癌,胃癌,皮肤癌有抑制效果。
Palonosetron HCl对肺癌,胃癌,皮肤癌有抑制效果。
Azelnidipine对肺癌,胃癌,肝癌,直肠癌,皮肤癌有抑制效果。
Diclofenac Diethylamine对肺癌,胃癌,皮肤癌有抑制效果。
Dexmedetomidine对肺癌,胃癌,皮肤癌有抑制效果。
Atovaquone(Atavaquone)对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,血癌有抑制效果。
Etravirine(TMC125)对肺癌,胃癌,结肠癌,皮肤癌,***癌,膀胱癌,血癌有抑制效果。
Nadifloxacin对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌有抑制效果。
Articaine HCl对皮肤癌有抑制效果。
Tylosin tartrate对肺癌有抑制效果。
Altrenogest对肺癌,直肠癌有抑制效果。
Atomoxetine HCl对直肠癌有抑制效果。
Brinzolamide对直肠癌有抑制效果。
Ropinirole HCl对直肠癌,皮肤癌有抑制效果。
Azlocillin sodium salt对肺癌,直肠癌有抑制效果。
Azacyclonol对肺癌,直肠癌,皮肤癌有抑制效果。
Reboxetine mesylate对直肠癌,皮肤癌有抑制效果。
Trifluoperazine 2HCl对胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,血癌有抑制效果。
Meptazinol HCl对***癌有抑制效果。
Fexofenadine HCl对肺癌,皮肤癌,***癌有抑制效果。
Amidopyrine对***癌有抑制效果。
Moclobemide对胃癌,***癌有抑制效果。
Pergolide mesylate对***癌有抑制效果。
Lithocholic acid对肺癌,胃癌,***癌有抑制效果。
Ethambutol HCl对皮肤癌,***癌有抑制效果。
Acebutolol HCl对直肠癌,皮肤癌,***癌有抑制效果。
Hyoscyamine(Daturine)对直肠癌,皮肤癌,***癌有抑制效果。
Ouabain对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,膀胱癌,***癌,血癌有抑制效果。
Procaine(Novocaine)HCl肺癌,胃癌,***癌,膀胱癌有抑制效果。
Hydroxyzine 2HCl对肺癌,胃癌,皮肤癌,***癌,膀胱癌有抑制效果。
Flavoxate HCl对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌有抑制效果。
Aclidinium Bromide对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌有抑制效果。
Bismuth Subsalicylate对肺癌,胃癌,直肠癌,***癌,膀胱癌有抑制效果。
Diphemanil methylsulfate对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌有抑制效果。
Doxapram HCl对肺癌,胃癌,肝癌,直肠癌,皮肤癌,***癌,膀胱癌有抑制效果。
Methazolamide对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌有抑制效果。
norethindrone对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Retapamulin对皮肤癌有抑制效果。
Ronidazole对结肠癌有抑制效果。
Hexamethonium bromide对结肠癌,皮肤癌,***癌有抑制效果。
Decamethonium bromide对***癌有抑制效果。
Isovaleramide对直肠癌,乳癌有抑制效果。
Penfluridol对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,血癌有抑制效果。
D-Phenylalanine对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Benzethonium chloride对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,血癌有抑制效果。
Cyclandelate对结肠癌有抑制效果。
Antazoline HCl对肺癌有抑制效果。
Azaperone对肺癌,乳癌有抑制效果。
Oxybuprocaine HCl对肺癌,乳癌有抑制效果。
Pilocarpine HCl对肺癌,乳癌有抑制效果。
Zoxazolamine对肺癌乳癌有抑制效果。
Doxylamine Succinate对肺癌,胃癌,结肠癌,皮肤癌,***癌,乳癌有抑制效果。
Serotonin HCl对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,膀胱癌,乳癌,血癌有抑制效果。
Anisotropine Methylbromide对肺癌,***癌,乳癌有抑制效果。
Bromocriptine Mesylate对肺癌,胃癌,***癌,乳癌有抑制效果。
Butacaine对肺癌,结肠癌,***癌,乳癌,血癌有抑制效果。
Dibenzepine HCl对肺癌,胃癌,肝癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Diphenylpyraline HCl对肺癌,胃癌,肝癌,结肠癌,皮肤癌,***癌,乳癌有抑制效果。
Nalmefene HCl对皮肤癌有抑制效果。
Oxethazaine对肺癌有抑制效果。
Physostigmine Salicylate对皮肤癌有抑制效果。
Pipenzolate Bromide对皮肤癌有抑制效果。
R-(-)-Apomorphine HCl Hemihydrate对肺癌,直肠癌,结肠癌,皮肤癌,膀胱癌有抑制效果。
Ractopamine HCl对肺癌,皮肤癌,膀胱癌有抑制效果。
Terfenadine对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,血癌有抑制 效果。
Tacrine HCl对肝癌,结肠癌,皮肤癌有抑制效果。
Pimozide对肺癌,胃癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Suxibuzone对膀胱癌有抑制效果。
Triflupromazine HCl对胃癌,直肠癌,皮肤癌,膀胱癌有抑制效果。
Dicyclomine HCl对肺癌有抑制效果。
Thioridazine HCl对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌有抑制效果。
Imipramine HCl对皮肤癌,膀胱癌,乳癌有抑制效果。
Nomifensine Maleate对肺癌,皮肤癌,乳癌有抑制效果。
Pyrilamine Maleate对皮肤癌,膀胱癌,乳癌有抑制效果。
Diperodon HCl对肺癌,胃癌,肝癌,结肠癌,皮肤癌,膀乳癌有抑制效果。
Prochlorperazine Dimaleate对肺癌,胃癌,肝癌,结肠癌,皮肤癌,膀胱癌,乳癌有抑制效果。
Quipazine Maleate对肺癌,胃癌,肝癌,结肠癌,皮肤癌,乳癌有抑制效果。
上列详细说明是针对本发明之一可行实施例的具体说明，惟该实施例并非用以限制本发明的专利范围，凡未脱离本发明技艺精神所为的等效实施或变更，均应包含于本发明的专利范围中。

Claims (9)

  1. 一种神经***疾病药物在制备抗癌医药组合物中的应用，其特征是，所述医药组合物是选自神经***疾病药物所组成的药物。
  2. 如权利要求1所述的应用，其特征是，所述神经***疾病药物是选自疼痛解除剂、精神治疗剂、神经药物、麻醉剂、抗胆碱剂(Parasympathomimetic(Cholinergic)Agents)及其他药物中的一种或多种。
  3. 如权利要求2所述的应用，其特征是，所述疼痛解除剂是选自Ketorolac(Toradol)、Diclofenac、Dexmedetomidine HCl(Precedex)、Acetanilide(Antifebrin)、Diclofenac Diethylamine、Meptazinol HCl、Amidopyrine、Procaine(Novocaine)HCl、Bextra(valdecoxib)、Nefopam HCl及Pyrilamine Maleate中的一种或多种。
  4. 如权利要求2所述的应用，其特征是，所述精神治疗剂是选自Agomelatine、Amisulpride、Asenapine、Fluoxetine HCl、Fluvoxamine maleate、Granisetron HCl、Mianserin hydrochloride、Tianeptine sodium、Venlafaxine、Ziprasidone hydrochloride、Iloperidone(Fanapt)、Risperidone(Risperdal)、Paliperidone(Invega)、Quetiapine fumarate(Seroquel)、Chlorprothixene、Aripiprazole(Abilify)、Chlorpromazine(Sonazine)、Lurasidone HCl、Azacyclonol、Reboxetine mesylate、Trifluoperazine 2HCl、Moclobemide、Loxapine Succinate、Droperidol、Penfluridol、Amoxapine、Serotonin HCl、Dibenzepine HCl、Pimozide、Triflupromazine HCl、Thioridazine HCl、Imipramine HCl、Nomifensine Maleate及Prochlorperazine Dimaleate中的一种或多种。
  5. 如权利要求2所述的应用，其特征是，所述神经药物是选自由Aprepitant(MK-0869)、Rufinamide(Banzel)、Felbamate、Levetiracetam、Oxcarbazepine、Rocuronium bromide、Vecuronium Bromide、Tizanidine HCl、Topiramate、Zonisamide、Naratriptan HCl、Rizatriptan Benzoate(Maxalt)、Carbamazepine(Carbatrol)、Levodopa(Sinemet)、Methocarbamol(Robaxin)、Atracurium besylate、Carbidopa、Tropisetron、Haloperidol(Haldol)、Primidone(Mysoline)、Pramipexole dihydrochloride monohydrate、Memantine HCl(Namenda)、Duloxetine HCl(Cymbalta)、Benserazide、Pramipexole(Mirapex)、Entacapone、Atomoxetine HCl、Brinzolamide、Ropinirole HCl、Pergolide mesylate、Droperidol及Imipramine HCl中的一种或多种。
  6. 如权利要求2所述的应用，其特征是，所述麻醉剂是选自Etomidate、Prilocaine、Proparacaine HCl、Cisatracurium besylate(Nimbex)、Bupivacaine hydrochloride(Marcain)、Dexmedetomidine、Oxybuprocaine HCl及Butacaine中的一种或多种。
  7. 如权利要求2所述的应用，其特征是，所述抗胆碱剂是选自Biperiden HCl、Oxybutynin(Ditropan)、Acetylcholine chloride、Bethanechol chloride、Pilocarpine HCl、Anisotropine Methylbromide、Physostigmine Salicylate及Procyclidine HCl中的一种或多种。
  8. 如权利要求2所述的应用，其特征是，所述其他药物是选自Vinblastine、Ramelteon(TAK-375)、Aniracetam、Flumazenil、Lidocaine(Alphacaine)、Mosapride citrate、Sumatriptan succinate、Varenicline tartrate、Riluzole (Rilutek)、Allopurinol(Zyloprim)、Zolmitriptan(Zomig)、Isradipine(Dynacirc)、Disulfiram(Antabuse)、Divalproex sodium、Chlorpheniramine Maleate、Dapoxetine hydrochloride(Priligy)、Nicotinamide(Niacinamide)、Tropicamide、Pregnenolone、Alibendol、Irsogladine、Nefiracetam(Translon)、Methscopolamine(Pamine)、Meclizine 2HCl、Formoterol hemifumarate、Ketotifen fumarate(Zaditor)、Ciprofloxacin(Cipro)、Fenticonazole nitrate、Cyproheptadine HCl(Periactin)、Gimeracil、Trimebutine、Ivabradine HCl(Procoralan)、Betaxolol(Betoptic)、Ambrisentan、Naltrexone HCl、Levosulpiride(Levogastrol)、Azasetron HCl(Y-25130)、Lapatinib、Dronedarone HCl(Multaq)、Fudosteine、Daxas、Sitafloxacin hydrate、Dabigatran etexilate,Pradaxa、Irinotecan HCl Trihydrate(Campto)、Clindamycin hydrochloride(Dalacin)、Domperidone(Motilium)、Estriol、Imatinib(Gleevec)、Nitrendipine、Olopatadine hydrochloride(Opatanol)、Pantothenic acid(pantothenate)、Sotalol(Betapace)、Maprotiline hydrochloride、Naphazoline hydrochloride(Naphcon)、Ciclopirox(Penlac)、Econazole nitrate(Spectazole)、Miconazole(Monistat)、Cefprozil hydrate(Cefzil)、Tolterodine tartrate(Detrol LA)、Azelastine hydrochloride(Astelin)、5-Aminolevulinic acid hydrochloride、Clarithromycin(Biaxin,Klacid)、Vancomycin HCl(Vancocin)、Clobetasol propionate、Miglitol(Glyset)、L-Thyroxine、Gliclazide(Diamicron)、Buflomedil HCl、PCI-32765(Ibrutinib)、Amoxicillin(Amoxycillin)、Cabazitaxel(Jevtana)、Niclosamide(Niclocide)、Azilsartan (TAK-536)、Palonosetron HCl、Azelnidipine、Atovaquone(Atavaquone)、Etravirine(TMC125)、Nadifloxacin、Oxybutynin chloride、Tripelennamine HCl、Ibandronate sodium、Articaine HCl、Butenafine HCl、Tylosin tartrate、Altrenogest、Azlocillin sodium salt、Fexofenadine HCl、Lithocholic acid、Ethambutol HCl、Acebutolol HCl、Hyoscyamine(Daturine)、Ouabain、Hydroxyzine 2HCl、Flavoxate HCl、Aclidinium Bromide、Bismuth Subsalicylate、Diphemanil methylsulfate、Doxapram HCl、Methazolamide、norethindrone、Pheniramine Maleate、Retapamulin、Ronidazole、Hexamethonium bromide、Decamethonium bromide、Aminosalicylate sodium、Sodium nitrite、Pramoxine HCl、Isovaleramide、D-Phenylalanine、Benzethonium chloride、Nicardipine HCl、Cyclandelate、Antazoline HCl、Tolperisone HCl、Azaperone、Zoxazolamine、Doxylamine Succinate、Bromocriptine Mesylate、Diphenylpyraline HCl、Physostigmine Hemisulfate Salt、Ethoxzolamide、Hemicholinium Bromide、Mesoridazine Besylate、Methapyrilene HCl、Nalmefene HCl、Nialamide、Oxethazaine、Pipenzolate Bromide、R-(-)-Apomorphine HCl Hemihydrate、Ractopamine HCl、Terfenadine、Tacrine HCl、Suxibuzone、Nicotine Ditartrate、Dicyclomine HCl、Diperodon HCl、Quipazine Maleate及amine Maleate中的一种或多种。
  9. 如权利要求1所述的应用，其特征是，所述癌症系选自由肺癌、肠道癌、大肠直肠癌、***癌、膀胱癌、子***、乳癌、皮肤癌中的一种或多种。
PCT/CN2015/092775 2014-10-24 2015-10-23 神经***疾病用药在制备抗癌医药组合物中的应用 WO2016062285A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24
US62/068,298 2014-10-24

Publications (1)

Publication Number Publication Date
WO2016062285A1 true WO2016062285A1 (zh) 2016-04-28

Family

ID=55760314

Family Applications (21)

Application Number Title Priority Date Filing Date
PCT/CN2015/092782 WO2016062291A1 (zh) 2014-10-24 2015-10-23 千忧解药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092702 WO2016062274A1 (zh) 2014-10-24 2015-10-23 消化***疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092780 WO2016062289A1 (zh) 2014-10-24 2015-10-23 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092761 WO2016062279A1 (zh) 2014-10-24 2015-10-23 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
PCT/CN2015/092617 WO2016062265A1 (zh) 2014-10-24 2015-10-23 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092632 WO2016062266A1 (zh) 2014-10-24 2015-10-23 氨氯地平在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092779 WO2016062288A1 (zh) 2014-10-24 2015-10-23 代谢性疾病药物用于制备抑制癌症的医药组合物的用途
PCT/CN2015/092771 WO2016062283A1 (zh) 2014-10-24 2015-10-23 抗发炎用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092714 WO2016062275A1 (zh) 2014-10-24 2015-10-23 阿折地平在制备治疗癌症的医药组合物中的用途
PCT/CN2015/092768 WO2016062281A1 (zh) 2014-10-24 2015-10-23 心血管疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092781 WO2016062290A1 (zh) 2014-10-24 2015-10-23 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092753 WO2016062278A1 (zh) 2014-10-24 2015-10-23 内分泌疾病用药在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092746 WO2016062277A1 (zh) 2014-10-24 2015-10-23 驱虫药用于制备抗癌医药组合物中的应用
PCT/CN2015/092777 WO2016062287A1 (zh) 2014-10-24 2015-10-23 山喜多药物在用于制备抑制癌症的医药组合物中的用途
PCT/CN2015/092775 WO2016062285A1 (zh) 2014-10-24 2015-10-23 神经***疾病用药在制备抗癌医药组合物中的应用
PCT/CN2015/092677 WO2016062270A1 (zh) 2014-10-24 2015-10-23 呼吸***疾病用药用于制备抗癌医药组合物的用途
PCT/CN2015/092697 WO2016062272A1 (zh) 2014-10-24 2015-10-23 免疫疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092776 WO2016062286A1 (zh) 2014-10-24 2015-10-23 脱克钙药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092666 WO2016062269A1 (zh) 2014-10-24 2015-10-23 阿那格雷在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092653 WO2016062267A1 (zh) 2014-10-24 2015-10-23 奈必洛尔在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092686 WO2016062271A1 (zh) 2014-10-24 2015-10-23 抗生素药物用于制备治疗癌症的医药组合物的用途

Family Applications Before (14)

Application Number Title Priority Date Filing Date
PCT/CN2015/092782 WO2016062291A1 (zh) 2014-10-24 2015-10-23 千忧解药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092702 WO2016062274A1 (zh) 2014-10-24 2015-10-23 消化***疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092780 WO2016062289A1 (zh) 2014-10-24 2015-10-23 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092761 WO2016062279A1 (zh) 2014-10-24 2015-10-23 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
PCT/CN2015/092617 WO2016062265A1 (zh) 2014-10-24 2015-10-23 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092632 WO2016062266A1 (zh) 2014-10-24 2015-10-23 氨氯地平在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092779 WO2016062288A1 (zh) 2014-10-24 2015-10-23 代谢性疾病药物用于制备抑制癌症的医药组合物的用途
PCT/CN2015/092771 WO2016062283A1 (zh) 2014-10-24 2015-10-23 抗发炎用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092714 WO2016062275A1 (zh) 2014-10-24 2015-10-23 阿折地平在制备治疗癌症的医药组合物中的用途
PCT/CN2015/092768 WO2016062281A1 (zh) 2014-10-24 2015-10-23 心血管疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092781 WO2016062290A1 (zh) 2014-10-24 2015-10-23 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092753 WO2016062278A1 (zh) 2014-10-24 2015-10-23 内分泌疾病用药在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092746 WO2016062277A1 (zh) 2014-10-24 2015-10-23 驱虫药用于制备抗癌医药组合物中的应用
PCT/CN2015/092777 WO2016062287A1 (zh) 2014-10-24 2015-10-23 山喜多药物在用于制备抑制癌症的医药组合物中的用途

Family Applications After (6)

Application Number Title Priority Date Filing Date
PCT/CN2015/092677 WO2016062270A1 (zh) 2014-10-24 2015-10-23 呼吸***疾病用药用于制备抗癌医药组合物的用途
PCT/CN2015/092697 WO2016062272A1 (zh) 2014-10-24 2015-10-23 免疫疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092776 WO2016062286A1 (zh) 2014-10-24 2015-10-23 脱克钙药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092666 WO2016062269A1 (zh) 2014-10-24 2015-10-23 阿那格雷在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092653 WO2016062267A1 (zh) 2014-10-24 2015-10-23 奈必洛尔在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092686 WO2016062271A1 (zh) 2014-10-24 2015-10-23 抗生素药物用于制备治疗癌症的医药组合物的用途

Country Status (9)

Country Link
US (7) US10098852B2 (zh)
EP (3) EP3222278B1 (zh)
JP (1) JP6539345B2 (zh)
KR (1) KR102490334B1 (zh)
CN (3) CN106999470A (zh)
AU (2) AU2015335391B2 (zh)
ES (1) ES2954860T3 (zh)
TW (21) TW201615194A (zh)
WO (21) WO2016062291A1 (zh)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106074474A (zh) * 2016-06-15 2016-11-09 中南大学湘雅医院 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
US20200179404A1 (en) * 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
EP3949959A4 (en) * 2019-04-04 2022-05-11 Daegu-Gyeongbuk Medical Innovation Foundation PHARMACEUTICAL COMPOSITION COMPRISING TRIMEBUTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USED AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (zh) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 五氟利多在制备治疗子宫内膜癌的药物中的应用
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用
US11911351B2 (en) 2018-01-30 2024-02-27 Apnimed, Inc. (Delaware) Methods for treating sleep apnea with combinations of atomoxetine and (R)-oxybutynin

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3708564A1 (en) 2005-12-28 2020-09-16 Vertex Pharmaceuticals Incorporated A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
AU2015370666B2 (en) 2014-12-22 2020-09-03 Arovella Therapeutics Limited Prevention and treatment of metastatic disease in thrombocytotic cancer patients
WO2017116049A1 (ko) * 2015-12-31 2017-07-06 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물
WO2018072135A1 (zh) 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 二氢吡啶类钙拮抗剂用于治疗癌症的用途
CN108066345A (zh) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 一种具有抗肿瘤作用的化合物
WO2019008516A2 (en) * 2017-07-03 2019-01-10 Menri Group Ltd. TREATMENT OF CANCER WITH DIHYDROPYRIDINES
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
KR101933805B1 (ko) 2017-10-17 2018-12-28 성균관대학교산학협력단 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물
CN108186652A (zh) * 2017-12-28 2018-06-22 深圳大学 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
FR3090084B1 (fr) 2018-12-18 2023-10-13 Securengy Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent.
US20220072089A1 (en) * 2018-12-19 2022-03-10 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
US20220202771A1 (en) * 2019-04-05 2022-06-30 University Of North Texas Health Science Center At Fort Worth Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging
US20220146492A1 (en) * 2019-04-11 2022-05-12 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (zh) * 2019-05-31 2019-08-30 天津科技大学 一种噻吨溴类化合物的应用
CN110742890A (zh) * 2019-10-24 2020-02-04 暨南大学 洛美利嗪在制备抗结肠癌药物中的应用
CN110840887A (zh) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 三氯苯达唑在制备治疗乳腺癌的药物中的应用
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN111067899B (zh) * 2020-01-08 2021-03-05 温州医科大学 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (zh) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途
CN111557941A (zh) * 2020-06-15 2020-08-21 浙江大学 Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用
CN111848717A (zh) * 2020-08-07 2020-10-30 四川大学 靶向调控线粒体能量代谢的化合物及其应用和药物
TW202214245A (zh) * 2020-08-10 2022-04-16 國立彰化師範大學 雙非癌藥物用於製備治療癌症之醫藥組合物的用途
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN112336725A (zh) * 2020-12-11 2021-02-09 吴照球 甲氧苄啶的医药新用途
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN112569215A (zh) * 2020-12-30 2021-03-30 东莞市人民医院 度米芬在制备防治结直肠癌的药物中的应用
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (zh) * 2021-06-28 2022-12-30 四川大学 Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途
CN115887455B (zh) * 2022-08-04 2024-04-05 北京大学人民医院 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721335B1 (en) * 1993-10-01 2005-08-31 Roche Palo Alto LLC Mycophenolate mofetil high dose oral suspensions
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물
AU746887B2 (en) * 1998-09-15 2002-05-02 Eli Lilly And Company Treatment of persistent pain
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
WO2002004406A2 (en) * 2000-07-07 2002-01-17 Trustees Of Tufts College 9-substituted minocycline compounds
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN1878556A (zh) * 2003-09-18 2006-12-13 康宾纳特克斯公司 ***的联合药物
KR20060124607A (ko) * 2003-11-06 2006-12-05 셀진 코포레이션 암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
EP1753425A4 (en) * 2004-05-12 2009-08-05 Biorunx Co Ltd THERAPEUTIC AGENT COMPRISING A NICOTINIC ACID OR DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
DK1753713T3 (en) * 2004-05-21 2016-11-28 Harvard College SYNTHESIS OF TETRACYCLINES AND ANALOGS THEREOF
CN1279980C (zh) * 2004-10-14 2006-10-18 孔庆忠 一种抗实体肿瘤药物组合物
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (zh) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 制备缬沙坦的方法
ES2661169T3 (es) * 2005-07-28 2018-03-27 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Compuestos de monofenol, bencenodiol, o sulfhidrilo para uso en el tratamiento de melanomas
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CN101099724A (zh) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 一种微粉化来曲唑及其组合物
CN101103976A (zh) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 一种含阿那曲唑的口服药物组合物及其制备工艺
US20100273868A1 (en) * 2007-01-05 2010-10-28 Cornerstone Therapeutics Inc. R-Zileuton for Use in Conditions Associated with Increased 5-Lipoxygenase and/or Leukotriene Activity (EG Asthma)
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (zh) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂
WO2009126274A2 (en) * 2008-04-08 2009-10-15 New York University School Of Medicine Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (zh) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 氨氯地平在制备治疗细胞增生性疾病药物中的用途
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
EP2303255A1 (en) * 2008-06-03 2011-04-06 Université Paris Diderot - Paris 7 Pharmaceutical compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN101991553B (zh) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 一种依西美坦片及其制备方法
CN101863806B (zh) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 抗***癌药物(r)-比卡鲁胺的制备方法
WO2011146583A2 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
JP5978424B2 (ja) * 2010-07-29 2016-08-24 国立大学法人京都大学 抗がん剤のスクリーニング方法
US20130261142A1 (en) * 2010-12-15 2013-10-03 Hung-Cheng Lai Compounds used for treating cancer and the use thereof
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
CN102688493B (zh) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN102813643B (zh) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 bumetanide在抑制肝癌细胞转移中的应用
EP2760473A1 (en) * 2011-09-27 2014-08-06 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
CN109985228A (zh) * 2011-11-10 2019-07-09 凯伊药品公司 拟钙剂及其使用方法
CN102600077B (zh) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 吉西他滨或其盐纳米乳剂注射液及其制备方法
ES2384069B1 (es) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet y tumores neuroblásticos
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014036654A1 (en) * 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
BR112015006176B1 (pt) * 2012-09-21 2023-04-18 Intensity Therapeutics, Inc Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
AR092899A1 (es) * 2012-10-04 2015-05-06 Ab Science Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
CN103356687B (zh) * 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
CN105142631A (zh) * 2013-01-14 2015-12-09 健康诊所有限公司 抗癌药物和用途
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (zh) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 阿那格雷及其衍生物的抗肿瘤用途
CN103396419A (zh) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法
CN103536925B (zh) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN103622975B (zh) * 2013-11-07 2016-06-15 广东药学院 格列吡嗪在制备***药物中的应用
KR20160143775A (ko) * 2014-04-08 2016-12-14 더 메서디스트 하스피틀 iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN NANA ET AL.: "Inhibtion of Diclofenac on Proliferation of Hepatoma Cells Expressing Cyclooxygenase-2", CHINESE PHARMACEUTICAL JOURNAL, vol. 42, no. 15, 31 August 2007 (2007-08-31), pages 1152 - 1155, ISSN: 1001-2494 *
MENG QINGWEI ET AL.: "Inhibitory Effect of Carbamazepine on Proliferation of Estrogen-Dependent Breast Cancer Cells", CHINESE JOURNAL OF CANCER, vol. 25, no. 8, 31 December 2006 (2006-12-31), pages 967 - 973, ISSN: 1000-467X *
SUN LIJUN ET AL.: "Effect of chlorpromazine on cell proliferation of cervical carcinoma Hela cell line in vitro", JOURNAL OF ZHENGZHOU UNIVERSITY( SCIENCE MEDICAL, vol. 40, no. 2, 31 March 2005 (2005-03-31), pages 344 - 345, ISSN: 1671-6825 *
SUN ZHIWEI ET AL.: "Efficacy and Predictive Molecule Markers Associated Toxicity of Irinotecan for Colorectal Cancer", CLINICAL MEDICATION JOURNAL, vol. 12, no. 2, 31 March 2014 (2014-03-31), pages 9 - 13, ISSN: 1672-3384 *
XI LIPING ET AL.: "Advances in research on vinblastine case antineoplastic", DRUG EVALUATION RESEARCH, vol. 34, no. 1, 28 February 2011 (2011-02-28), pages 59 - 62, ISSN: 1674-6376 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (zh) * 2016-06-15 2016-11-09 中南大学湘雅医院 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US10980753B2 (en) 2016-12-20 2021-04-20 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US20200179404A1 (en) * 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11911351B2 (en) 2018-01-30 2024-02-27 Apnimed, Inc. (Delaware) Methods for treating sleep apnea with combinations of atomoxetine and (R)-oxybutynin
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3949959A4 (en) * 2019-04-04 2022-05-11 Daegu-Gyeongbuk Medical Innovation Foundation PHARMACEUTICAL COMPOSITION COMPRISING TRIMEBUTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USED AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (zh) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 五氟利多在制备治疗子宫内膜癌的药物中的应用
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用

Also Published As

Publication number Publication date
TW201615220A (zh) 2016-05-01
TW201615195A (zh) 2016-05-01
TWI672150B (zh) 2019-09-21
TW201615197A (zh) 2016-05-01
WO2016062274A1 (zh) 2016-04-28
AU2015335375B2 (en) 2020-09-10
CN106999470A (zh) 2017-08-01
AU2015335375A1 (en) 2017-05-18
TWI663969B (zh) 2019-07-01
WO2016062290A1 (zh) 2016-04-28
WO2016062277A1 (zh) 2016-04-28
EP3235497A1 (en) 2017-10-25
WO2016062271A1 (zh) 2016-04-28
TW201615222A (zh) 2016-05-01
AU2015335391A1 (en) 2017-06-01
EP3210604C0 (en) 2024-02-14
US10045962B2 (en) 2018-08-14
CN107106550A (zh) 2017-08-29
ES2954860T3 (es) 2023-11-27
TW201615221A (zh) 2016-05-01
TW201615184A (zh) 2016-05-01
US20170216247A1 (en) 2017-08-03
WO2016062270A1 (zh) 2016-04-28
TW201615191A (zh) 2016-05-01
WO2016062283A1 (zh) 2016-04-28
TWI652060B (zh) 2019-03-01
EP3222278A4 (en) 2018-06-20
EP3222278C0 (en) 2023-06-14
TW201615192A (zh) 2016-05-01
US20170304218A1 (en) 2017-10-26
JP2017532351A (ja) 2017-11-02
US20170304286A1 (en) 2017-10-26
EP3210604A1 (en) 2017-08-30
WO2016062289A1 (zh) 2016-04-28
AU2015335391B2 (en) 2018-06-21
TW201615193A (zh) 2016-05-01
EP3222278A1 (en) 2017-09-27
WO2016062267A1 (zh) 2016-04-28
EP3222278B1 (en) 2023-06-14
US20170312260A1 (en) 2017-11-02
JP6539345B2 (ja) 2019-07-03
WO2016062278A1 (zh) 2016-04-28
WO2016062266A1 (zh) 2016-04-28
WO2016062286A1 (zh) 2016-04-28
EP3210604B1 (en) 2024-02-14
TWI663984B (zh) 2019-07-01
TW201615224A (zh) 2016-05-01
TW201615189A (zh) 2016-05-01
WO2016062281A1 (zh) 2016-04-28
KR20170084034A (ko) 2017-07-19
TW201615188A (zh) 2016-05-01
TW201615219A (zh) 2016-05-01
WO2016062269A1 (zh) 2016-04-28
TW201615194A (zh) 2016-05-01
US20170304387A1 (en) 2017-10-26
EP3210604A4 (en) 2018-06-27
KR102490334B1 (ko) 2023-01-18
US20170304388A1 (en) 2017-10-26
CN107106523A (zh) 2017-08-29
TW201615223A (zh) 2016-05-01
WO2016062265A1 (zh) 2016-04-28
TW201615217A (zh) 2016-05-01
TW201615226A (zh) 2016-05-01
WO2016062291A1 (zh) 2016-04-28
TW201615218A (zh) 2016-05-01
WO2016062287A1 (zh) 2016-04-28
WO2016062272A1 (zh) 2016-04-28
WO2016062279A1 (zh) 2016-04-28
US10098852B2 (en) 2018-10-16
WO2016062288A1 (zh) 2016-04-28
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
TWI621434B (zh) 2018-04-21
EP3235497A4 (en) 2018-06-13
WO2016062275A1 (zh) 2016-04-28
TW201615186A (zh) 2016-05-01
TW201615196A (zh) 2016-05-01
TW201615225A (zh) 2016-05-01

Similar Documents

Publication Publication Date Title
WO2016062285A1 (zh) 神经***疾病用药在制备抗癌医药组合物中的应用
Backonja et al. Pharmacologic management part 1: better-studied neuropathic pain diseases
Aveline et al. Postoperative analgesia and early rehabilitation after total knee replacement: a comparison of continuous low-dose intravenous ketamine versus nefopam
CN104994850A (zh) 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
KR20070085838A (ko) 운동 장애의 치료 방법
CA3062247A1 (en) Methods of treating doose syndrome using fenfluramine
Viswanath et al. Does pre-emptive administration of intravenous ibuprofen (Caldolor) or intravenous acetaminophen (Ofirmev) reduce postoperative pain and subsequent narcotic consumption after third molar surgery?
JP2022050564A (ja) リソソーム蓄積障害に関する医薬組成物及び使用
AU2003301188B2 (en) Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
Hauer et al. Pediatric pain and symptom management guidelines
Gourlay et al. A controlled study of a serotonin reuptake blocker, zimelidine, in the treatment of chronic pain
Lambertz et al. NO SToPS: Reducing treatment breaks during chemoradiation for head and neck cancer
JP2011121976A (ja) 線維筋痛症に伴う口腔乾燥症を改善するための線維筋痛症に伴う口腔乾燥症改善用医薬組成物
Demaagd High-risk drugs in the elderly population: Nurses, who are at the front lines of health care in all areas of practice, should be aware of drugs that may cause serious problems for elderly patients
Ghezal et al. Ropivacaine versus placebo on postoperative analgesia and chronic pain following third molar extraction: a prospective randomized controlled study
Kamel et al. Magnesium sulphate within multimodal analgesia, pre-emptive, or preventive analgesia
CN117177741A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和***素的组合
Ferini-Strambi et al. Treatment of restless legs syndrome
Markowitz Symptomatic therapy of multiple sclerosis
Moline Pain management in the ambulatory surgical population
Nanjegowda et al. The effects of intrathecal midazolam on the duration of analgesia in patients undergoing knee arthroscopy
EP3556363A1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
JP2022541634A (ja) 疼痛に関連する睡眠障害を治療する方法
JPWO2019124507A1 (ja) 夜間頻尿治療剤
Farooq et al. Headache and chronic facial pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15852192

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15852192

Country of ref document: EP

Kind code of ref document: A1